




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :	A1	(11) International Publication Number: WO 95/28419 (43) International Publication Date: 26 October 1995 (26.10.95)
C07K 5/078, 5/097, A61K 38/05, 38/06		
(21) International Application Number:	PCT/US95/04163	(81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).
(22) International Filing Date:	12 April 1995 (12.04.95)	
(30) Priority Data:		
9407433.3	14 April 1994 (14.04.94)	GB
9420783.4	14 October 1994 (14.10.94)	GB
(71) Applicant (for all designated States except US): GLAXO WELLCOME INC. [US/US]; Five Moore Drive, Research Triangle Park, NC 27709 (US).	Published	With international search report.
(72) Inventors; and		
(75) Inventors/Applicants (for US only): AQUINO, Christopher, Joseph [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). SUGG, Elizabeth, Ellen [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US). SZEWCZYK, Jerzy, Ryszard [US/US]; Glaxo Wellcome Inc., Five Moore Drive, Research Triangle Park, NC 27709 (US).		
(74) Agents: SMITH, Gardiner, F., H.; Glaxo Wellcome Inc., 5 Moore Drive, Research Triangle Park, NC 27709 (US) et al.		

(54) Title: CCK OR GASTRIN MODULATING 5-HETEROCYCLIC-1,5-BENZODIAZEPINES



(57) Abstract

Compounds of general formula (I) and physiologically salts thereof, processes for their preparation and their use as modulators of the effects of gastrin and CCK.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

CCK OR GASTRIN MODULATING 5-HETEROCYCLIC-1,5-BENZODIAZEPINES

This invention relates to 5-heterocyclo-1,5-benzodiazepine derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medicine. More particularly, it relates to compounds which exhibit agonist activity for CCK-A receptors thereby enabling them to modulate the hormones gastrin and cholecystokinin (CCK) in mammals.

Cholecystokinins (CCK) and gastrin are structurally related peptides which exist in gastrointestinal tissue and in the central nervous system. Cholecystokinins include CCK-33, a neuropeptide of thirty-three amino acids in its originally isolated form, its carboxyl terminal octapeptide, CCK-8 (also a naturally occurring neuropeptide), and 39- and 12-amino acid forms. Gastrin occurs in 34-, 17- and 14- amino acid forms, with the minimum active sequence being the C-terminal tetrapeptide, Trp-Met-Asp-Phe-NH₂ (CCK-4) which is the common structural element shared by both CCK and gastrin.

CCK and gastrin are gastrointestinal hormones and neurotransmitters in the neural and peripheral systems and perform their respective biological roles by binding to particular receptors located at various sites throughout the body. There are at least two subtypes of cholecystokinin receptors termed CCK-A and CCK-B and both are found in the periphery and in the central nervous system.

The CCK-A receptor, commonly referred to as the "peripheral-type" receptor, is primarily found in the pancreas, gallbladder, ileum, pyloric sphincter and on vagal afferent nerve fibers. Type-A CCK receptors are also found in the brain in discrete regions and serve to provide a number of CNS effects. Due to the ability of CCK-8 and Type-A CCK-selective agonists to suppress food intake in several animal species, considerable interest has been generated toward the development of new substances which function as Type-A receptor-selective CCK agonists in order to serve as anorectic agents.

The CCK-B or gastrin receptors are found in peripheral neurons, gastrointestinal smooth muscle and gastrointestinal mucosa, most notably in parietal cells, ECL cells, D cells and chief cells. CCK-B receptors also predominate in the brain and

have been implicated in the regulation of anxiety, arousal and the action of neuroleptic agents.

U.S. Patent No. 4,988,692, to Gasc, et al. describes a group of 3-acylamino 1-alkyl-
5 5-phenyl 1,5-benzodiazepine derivatives which behave as cholecystokinin
antagonists to reverse or block the effects of the endogenous hormone at its
receptors.


US Patent No. 4,490,304 and PTC applications No's WO90/06937 and
10 WO91/19733 describe peptide derivatives that exhibit CCK-A agonist activity. Such
compounds have been disclosed for appetite regulation as well as the treatment
and/or prevention of gastrointestinal disorders or disorders of the central nervous in
animals and, more particularly, humans.

15 US Patent No. 5,187,154 which is incorporated herein by reference describes the
use of the neuropeptide cholecystokinin (CCK) to control gastric emptying in
patients having an early non-insulin-dependent diabetic condition and exhibiting
rapid gastric emptying. Further the specification teaches that compounds which
inhibit gastric emptying may be useful to alleviate or eliminate symptoms associated
20 with early or pre-diabetes. Particular symptoms include elevated blood glucose and
insulin levels, insulin resistance, increased susceptibility to infection or glycosuria
while also maintaining gastric emptying within normal levels.

We have now discovered a novel group of 5-heterocyclo-1,5-benzodiazepine
25 derivatives which exhibit an agonist activity for the CCK-A receptor thereby
enabling them to modulate the hormones gastrin and cholecystokinin (CCK) in
mammals. Certain of these compounds also exhibit antagonist activity at CCK-B
receptors.

30 The present invention thus provides compounds of the general Formula (I)

3




and physiologically salts and solvate thereof wherein:

X is either hydrogen, trifluoromethyl, alkyl, C₁-4alkylthio, -O(C₁-4alkyl) or halogen;

5

R¹ is either Formula II or -NR⁴R⁵:



R² is either:

10

(1) a heterocycle linked at its 2- position and selected from pyrrole, tetrahydropyrrole, indole, benzofuran, thiophene, benzothiophene, indoline, quinoline or 4-oxobenzopyran and wherein said pyrrole, tetrahydropyrrole, indole or indoline may optionally be substituted on the ring nitrogen thereof by the group R⁸ as defined hereunder and said indole, indoline, quinoline, benzofuran, benzothiophene or 4-oxo-benzopyran may optionally be substituted in the benzo ring thereof by the group R⁹ as defined hereunder or

15

(2) phenyl or phenyl mono- or disubstituted independently with halogen; hydroxy, cyano, carboxy, -O(C₁-4alkyl), -O(CH₂C₆H₅), -COO(C₁-4alkyl), amino, dimethylamino, -NHR¹⁰, 1-pyrrolidinyl or tetrazolyl; or

- (3) pyridine or pyridinyl mono- or disubstituted independently with halogen, methyl, hydroxy, nitro, cyano, carboxy, -O(C₁₋₄ alkyl), -O(CH₂C₆H₅), -COO(C₁₋₄ alkyl), amino or dimethylamino; or
- 5 (4) -NHR¹¹ where R¹¹ is defined hereinunder or R¹¹ is 7-indazolyl containing a group R¹⁰ at the N-1 position;
- R³ is a heterocyclic group (attached to the rest of the molecule via a carbon atom ring member thereof), selected from pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, furanyl, thiophenyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiazole, pyrrolidinyl, piperidinyl, morpholinyl or thiomorpholinyl which heterocyclic groups may be substituted with up to 3 substituents which may be the same or different and selected from halogen, C₁₋₄ alkyl, nitro, carboxyl, C₁₋₄ alkoxy carbonyl, C₁₋₄ alkoxy, C₁₋₄ alkylthio, amino, C₁₋₄ alkylamino or di(C₁₋₄ alkyl)amino.
- R⁴ is independently C₃₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆alkenyl, phenyl, -(CH₂)_pCN or -(CH₂)_pCOO(C₁₋₄ alkyl) and R⁵ is independently C₃₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆alkenyl, benzyl, phenyl or phenyl mono- or disubstituted independently with C₁₋₃ alkyl optionally substituted by one or more fluorine atoms, cyano, hydroxy, dimethylamino, -O(C₁₋₄ alkyl), -O(CH₂C₆H₅), -NH(C₁₋₄ alkyl), -COO(C₁₋₄ alkyl), -N(C₁₋₄ alkyl)₂ pyrrolidino, morpholino or halogen or R⁴ is C₁₋₂alkyl and R⁵ is phenyl substituted at the 2- or 4- position with chloro, methyl, methoxy or methoxycarbonyl;
- 25 R⁶ is hydrogen or methyl;
- R⁷ is hydrogen, hydroxy, fluoro, dimethylamino, -O(C₁₋₄ alkyl) or -O(CH₂C₆H₅);
- R⁸ is -(CH₂)_bCOOH;
- 30 R⁹ is methyl, chloro, nitro, hydroxy, methoxy or -NHR¹⁰;
- R¹⁰ is hydrogen, acetyl, C₁₋₄ alkyl, -SO₃H, -SO₂CH₃, -SO₂CF₃ or -SO₂C₆H₅, C₁₋₄ alkoxy carbonyl;


R¹¹ is phenyl or phenyl mono- or disubstituted independently with fluorine, trifluoromethoxy, C₁₋₄alkylthio, -(CH₂)_cCOOH, -(CH₂)_cCOO(C₁₋₄alkyl), -(CH₂)_cSCH₃, -(CH₂)_cSOCH₃, -(CH₂)_cSO₂CH₃, -(CH₂)_cCONH₂, -SCH₂COOH, -CONH(SO₂CH₃), -CONH(SO₂CF₃), -(CH₂)_cN(C₁₋₄alkyl)₂, -(CH₂)_cNH(SO₂CF₃), -

5 (CH₂)_cN(SO₂CF₃)(C₁₋₄alkyl), -(CH₂)_cSO₂NHCO(C₁₋₄alkyl), -(CH₂)_cSO₂N(C₁₋₄alkyl)CO(C₁₋₄alkyl), -(CH₂)_cCONHSO₂(C₁₋₄alkyl), -(CH₂)_cCON(C₁₋₄alkyl)SO₂(C₁₋₄alkyl), -(CH₂)_cOR¹² -(CH₂)_cNHR¹⁰ or phenyl monosubstituted with -(CH₂)_c(tetrazolyl), -(CH₂)_c (carboxamidotetrazolyl) or -(CH₂)_c(pyrrolidinyl) or R¹¹ is selected from pyridine or pyridinyl mono- or disubstituted independently with

10 halogen, methyl, hydroxy, nitro, cyano, carboxy, -O(C₁₋₄ alkyl), amino, dimethylamino, -NHR¹⁰;

R¹² is hydrogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, -CH₂C₆H₅, -CH₂COOH, -CH₂CONH₂, -CH₂CONH(C₁₋₄alkyl), -CH₂CON(C₁₋₄alkyl)₂ or

15



z is 1 or 2;

n is 1 or 2;

20

p is an integer from 1-4;

b is an integer from 0-3; and

25 c is 0 or 1.

When R¹ represents the group of Formula (II), examples of such a group include those wherein R⁶ is hydrogen or more particularly methyl, R⁷ is hydrogen, hydroxyl, methoxy, or fluorine, and n is 1.

30

When R¹ represents the group NR⁴R⁵, examples of suitable groups include those wherein R⁴ represent C₃₋₆ alkyl, such as propyl or isopropyl, cyclohexyl or phenyl and R⁵ represents C₃₋₆ alkyl, benzyl or phenyl optionally substituted in the para-position by hydroxy, dimethylamino methoxy, trifluoromethyl, fluorine, pyrrolidino or

morpholino. Within this group, particularly useful R¹ groups include those wherein R⁴ is propyl and, more particularly, isopropyl and R⁵ represents phenyl or phenyl substituted in the para-position by groups selected from hydroxy, methoxy dimethylamino, fluorine, or morpholino.

5


Examples of particularly suitable R¹ groups include those wherein R¹ is the group of Formula (II) wherein R₆ is methyl, n is 1 and R⁷ is hydrogen, hydroxy, fluorine or methoxy or R¹ is the group NR⁴R⁵ wherein R⁴ is propyl or isopropyl and R⁵ is phenyl optionally substituted in the para position by a group selected from hydroxy,

10 methoxy, fluoro, dimethylamino, pyrrolidino or morpholino. A particularly interesting R¹ group is that wherein R⁴ is isopropyl and R⁵ is 4-methoxyphenyl

When R² represents a group selected from indole, indoline, benzofuran, benzothiophene, quinoline or 4-oxobenzopyran, the optional substituent R⁹ is conveniently a group selected from hydrogen, methyl, methoxy, hydroxy, nitro or amino and, where appropriate, the optional substituent on nitrogen, (R⁸), is -
15 CH₂CO₂H.

When R² is an optionally substituted phenyl group, this is conveniently phenyl or
20 phenyl substituted by one or two groups, which may be the same or different and selected from chlorine, fluorine, amino, hydroxy or carboxyl.

When R² represents the group NHR¹¹, R¹¹ is conveniently phenyl (optionally substituted by fluoro, hydroxy, amino, dimethylamino,
25 trifluoromethylsulphonylamino, C₁₋₄ alkoxy carbonyl, carboxy, 1H-tetrazol-5-yl, acetyl amino or OR¹² wherein R¹² represents hydrogen, methyl, benzyl, CH₂CO₂H, CH₂CONH₂, CH₂CONHCH₃, CH₂CON(CH₃)₂



30 or a 7-indazolyl group wherein the N-1 substituent, (R¹⁰), is hydrogen.

When R¹¹ is a mono substituted phenyl group, the substituted is conveniently in the meta- position.

Examples of particularly suitable R² groups includes indole, benzofuran, thiophene, benzothiophene, indoline, quinoline, 4-oxobenzopyran, an optionally substituted phenyl group or the group NHR¹¹. Conveniently, R² is selected from the group
 5 indole, indoline or benzofuran, an optionally substituted phenyl group or the group NHR¹¹. More particularly, R² represents an indole, an optionally substituted phenyl or NHR¹¹.


When R³ represents pyridyl examples of suitable groups including 2-pyridyl, 3-
 10 pyridyl and 4-pyridyl.

When R³ represents pyrimidinyl example of suitable groups include 2-pyrimidinyl, or 5-pyrimidinyl.

15 When R³ represents pyrazolyl examples of suitable groups include 1,3,5-trimethyl-1H-pyrazole-4-yl.

Examples of particularly suitable R³ groups include pyridyl e.g 2-pyridyl, 3-pyridyl, 4-pyridyl, pyrimidinyl e.g. 2-pyrimidinyl, or 5-pyrimidinyl or 1, 3, 5-trimethyl-1H-
 20 pyrazol-4-yl.

A particularly useful group of compounds according to the invention include those wherein R¹ represents the group NR⁴R⁵ wherein R⁴ is propyl or isopropyl and R⁵ is phenyl optionally substituted in the para position by a group selected from hydroxy,
 25 methoxy, fluoro, dimethylamino or monopholino; R² represents phenyl (optionally substituted independently by one or two groups selected from chlorine, fluorine, hydroxy, amine or carboxy), NHR¹¹ wherein R¹¹ represents phenyl (optionally substituted by amino, dimethylamino, trifluoromethyl- sulphonyl amino, carboxy, 1H-tetrazol-5-yl, acetyl amino or OR¹² wherein R¹² represents hydrogen, methyl,
 30 benzyl, CH₂CO₂H, CH₂CONH₂, CH₂CONHCH₃, CH₂CON(CH₃)₂.



wherein the substituent is preferably in the meta- position) or an indole wherein the nitrogen atom is optionally substituted by the group -CH₂CO₂H and the benzo ring is optionally substituted by chlorine, methyl, methoxy, nitro, hydroxy or amino; R³ represents pyridyl e.g. 2, 3 or 4 pyridyl, pyrimidinyl e.g 2 or 5 pyrimidinyl or 1, 2, 5-5 trimethyl-1H-pyrazol-4-yl and X is hydrogen or fluorine.

A particularly interesting class of compounds of the present invention which exhibits a very high and selective affinity for the CCK-A receptor as well as exceptional efficacy occurs wherein R² is an indole group. A preferred group of compounds 10 within this class are those wherein the indole group is substituted on the nitrogen atom by the group -CH₂CO₂H or, more preferably, the nitrogen atom is unsubstituted, and benzo ring of the indole group is optionally substituted by a group selected from chlorine, methyl, methoxy, nitro, hydroxy or amino. Within this group especially useful compounds are those wherein R⁴ represents isopropyl, R⁵ 15 represents p-methoxy phenyl and R³ represents pyridyl, pyrimidinyl or 1, 3, 5-triemethyl-1H pyrazol-4-yl or more particularly R³ represents 3-pyridyl and X represents hydrogen.

Preferred compounds of the invention include:

20 1H-Indole-2-carboxylic acid {1-[Isopropyl-(4-methoxy-phenyl)-carbamoylmethyl]-2,4-dioxo-5-pyridin-2-yl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl}-amide;
1H-Indole-2-carboxylic acid {1-[Isopropyl-(4-methoxy-phenyl)-carbamoylmethyl]-2,4-dioxo-5-pyrimidin-2-yl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl}-amide;
2-[2,4-Dioxo-3-(3-phenyl-ureido)-5-pyridin-2-yl-2,3,4,5-tetrahydro-
25 benzo[b][1,4]diazepin-1-yl]-N-isopropyl-N-(4-methoxy-phenyl)-acetamide and enantiomers thereof.

A particularly preferred compound of the invention is
1H-Indole-2-carboxylic acid {1-[isopropyl-(4-methoxy-phenyl)-carbamoylmethyl]-2,4-dioxo-5-pyridin-3-yl-2,3,4,5-tetrahydro-1H-benzo [b][1,4] diazepin-3-yl}-amide; and enantiomers thereof.

As provided herein, the term alkyl is generally intended to mean both straight chain 35 and branched chain aliphatic isomers of the corresponding alkyl. For example, C₁-

alkyl is intended to include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tertbutyl, n-pentyl, etc.

The term cycloalkyl, as provided herein, is intended to mean all alicyclic isomers of 5 the corresponding alkyl. For example, the term C₃₋₆ alkyl, as provided herein, is intended to include such groups as cyclopropyl, cyclopentyl and cyclohexyl.

The term halogen is intended to mean F, Cl, Br or I.

10 The term tetrazole as a group or part of a group refers to the (1 H)-tetrazol-5-yl grouping and tautomers thereof.

Those skilled in the art will recognize that stereocenters exist in compounds of Formula (I). Accordingly, the present invention includes all possible stereoisomers 15 and geometric isomers of Formula (I) and includes not only racemic compounds but also the optically active isomers as well. When a compound of Formula (I) is desired as a single enantiomer, it may be obtained either by resolution of the final product or by stereospecific synthesis from either isomerically pure starting material or any convenient intermediate. Resolution of the final product, an intermediate or a 20 starting material may be effected by any suitable method known in the art. See, for example, Stereochemistry of Carbon Compounds by E. L. Eliel (Mcgraw Hill, 1962) and Tables of Resolving Agents by S. H. Wilen. Additionally, in situations where tautomers of the compounds of Formula (I) are possible, the present invention is intended to include all tautomeric forms of the compounds.

25 It will also be appreciated by those skilled in the art that the compounds of the present invention may also be utilized in the form of a pharmaceutically acceptable salt or solvate thereof. The physiologically acceptable salts of the compounds of Formula (I) include conventional salts formed from pharmaceutically acceptable 30 inorganic or organic acids as well as quaternary ammonium acid addition salts. More specific examples of suitable salts include hydrochloric, hydrobromic, sulphuric, phosphoric, nitric, perchloric, fumaric, acetic, propionic, succinic, glycolic, formic, lactic, maleic, tartaric, citric, pamoic, malonic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, fumaric, toluenesulphonic, methanesulphonic, 35 naphthalene-2-sulphonic, benzenesulphonic and the like. Other acids such as

oxalic, while not in themselves pharmaceutically acceptable, may be useful in the preparation of salts useful as intermediates in obtaining the compounds of the invention and their pharmaceutically acceptable salts. References hereinafter to a compound according to the invention include both compounds of Formula (I) and 5 their pharmaceutically acceptable salts and solvates.

The compounds of the present invention exhibit CCK-A agonist activity and can be considered full or partial cholecystokinin agonists in that they bind to CCK-A receptors and either fully or partially stimulate gallbladder contraction and/or reduce 10 feeding in animal paradigms.

As agonists of CCK-A receptors, the compounds of the present invention are useful anorectic agents advantageous in the treatment of obesity as well as related pathologies, such as diabetes or hypertension. Moreover, the compounds disclosed 15 herein provide for new approaches for inducing satiety, providing for appetite regulation and modifying food intake in mammals, especially humans, to regulate appetite, treat obesity and maintain weight loss. The compounds are also useful for the treatment of non-insulin dependent diabetic conditions associated with rapid gastric emptying.

20 Additionally, certain compounds of the present invention may also exhibit some antagonist activity at particular site-specific CCK-B and gastrin receptors as demonstrated by their inhibition of CCK-4 stimulated contraction of isolated guinea-pig ileum longitudinal muscle-myenteric plexus and pentagastrin-stimulated acid 25 secretion in rat isolated gastric mucosa using the procedures described by M. Patel and C. F. Spraggs in Br. J. Pharmac., (1992), 106, 275-282 and by J. J. Reeves and R. Stables in Br. J. Pharmac., (1985), 86, 677-684.

The relative affinities of compounds of the invention for the CCK-A and CCK-B 30 receptors may be determined using known conventional procedures such as described by Fornos et al J. Pharmacol Exp. Ther., 1992 261, 1056-1063.

The ability of compounds of the invention to inhibit gastric acid secretion, such as pentagastrin stimulated acid secretion may be determined in the conscious gastric

fistula rat using methods described by Hedges and Parsons Journal of Physiology 1977, 267 191-194.

The compounds of formula (I) inhibit or delay gastric emptying and this may be 5 determined using standard tests. Thus for example rats deprived for food for 18hr may be pretreated with the test compound administered i.p at a pre-set time (20 mins) before being given a methyl cellulose meal which is administered by the gavage route. The meal contains a marker element such as Phenol Red. After specific predetermined time intervals the rats are sacrificed and the amount of the 10 meal in the stomach is determined by measuring the concentration of the marker substance present. This value is then compared with a control animal which was not pre-treated with the test compound.

Compounds of the invention have been found to have a particularly advantageous 15 profile of activity in terms of good oral bioavailability coupled with relatively good water solubility.

In particular, the invention provides a compound of Formula (I) or a 20 pharmaceutically acceptable salt or solvate thereof for use in therapy, and in particular, in human medicine.

According to another aspect, the present invention provides the use of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof for the manufacture of a medicament for the treatment of conditions where modification of 25 the effects of CCK and/or gastrin is of therapeutic benefit.

According to a further aspect of the present invention, there is provided herein a method for the treatment of a mammal, including man, in particular in the treatment conditions where modification of the effects of CCK and/or gastrin is of therapeutic 30 benefit, the method comprising administering to the patient an therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt or solvate thereof.

It will be appreciated by those skilled in the art that reference herein to treatment 35 extends to prophylaxis as well as the treatment of established diseases or

- symptoms. Moreover, it will be appreciated that the amount of a compound of the invention required for use in treatment will vary with the nature of the condition being treated and the age and the condition of the patient and will be ultimately at the discretion of the attendant physician or veterinarian. In general, however, doses 5 employed for adult human treatment will typically be in the range of 0.02 - 5000 mg per day, e.g., 1-1500 mg per day. The desired dose may conveniently be presented in a single dose or as divided doses administered at appropriate intervals, for example as two, three, four or more sub-doses per day.
- 10 While it is possible that compounds of the present invention may be therapeutically administered as the raw chemical, it is preferable to present the active ingredient as a pharmaceutical formulation. Accordingly, the present invention further provides for a pharmaceutical formulation comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof together with one or more pharmaceutically 15 acceptable carriers therefore and, optionally, other therapeutic and/or prophylactic ingredients. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- 20 Formulations of the present invention include those especially formulated for oral, buccal, parenteral, implant, or rectal administration, however, oral administration is preferred. For buccal administration, the composition may take the form of tablets or lozenges formulated in conventional manner. Tablets and capsules for oral administration may contain conventional excipients such as binding agents, (for 25 example, syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch or polyvinylpyrrolidone), fillers (for example, lactose, sugar, microcrystalline cellulose, maize-starch, calcium phosphate or sorbitol), lubricants (for example, magnesium stearate, stearic acid, talc, polyethylene glycol or silica), disintegrants (for example, potato starch or sodium starch glycollate) or wetting agents, such as sodium lauryl 30 sulphate. The tablets may be coated according to methods well-known in the art. Suitable tablet coatings include conventional enteric coatings.

Alternatively, the compounds of the present invention may be incorporated into oral liquid preparations such as aqueous or oily suspensions, solutions, emulsions, 35 syrups or elixirs, for example. Moreover, formulations containing these compounds

- may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents such as sorbitol syrup, methyl cellulose, glucose/sugar syrup, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminum stearate
- 5 gel or hydrogenated edible fats; emulsifying agents such as lecithin, sorbitan monooleate or acacia; non-aqueous vehicles (which may include edible oils) such as almond oil, fractionated coconut oil, oily esters, propylene glycol or ethyl alcohol; and preservatives such as methyl or propyl *p*-hydroxybenzoates or sorbic acid.
- Such preparations may also be formulated as suppositories, e.g., containing
- 10 conventional suppository bases such as cocoa butter or other glycerides.

For oral administration the compounds of the invention are conveniently administered as enteric coated tablets or capsules made from enteric materials or coated with an enteric film.

- 15 Additionally, compositions the present invention may be formulated for parenteral administration by injection or continuous infusion. Formulations for injection may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for
- 20 constitution with a suitable vehicle (e.g., sterile, pyrogen-free water) before use.

- The composition according to the invention may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation
- 25 (for example, subcutaneously or intramuscularly) or by intramuscular injection. Accordingly, the compounds of the invention may be formulated with suitable polymeric or hydrophobic materials (as an emulsion in an acceptable oil, for example), ion exchange resins or as sparingly soluble derivatives as a sparingly soluble salt, for example.

- 30 The compositions according to the invention may contain between 0.1 - 99% of the active ingredient, conveniently from 30 - 95% for tablets and capsules and 3 - 50% for liquid preparations.

Compounds of general formula (I) and salts thereof may be prepared by the general methods outlined hereinafter. In the following description, the groups R¹-R¹² and X are as defined for the compounds of formula (I) unless otherwise stated or may be groups convertible thereto.

5

Thus for any of these processes, it may be necessary and/or desirable to protect sensitive or reactive groups. Protecting groups are employed according to standard methods of organic synthesis (T.W. Green and P. G. M Watts (1991) Protecting Groups in Organic Synthesis, John Wiley & Sons). These groups are removed at a


10 convenient stage of synthesis using methods known from the art. Thus, for example, amino groups may be protected by a group selected from arylmethyl (e.g. benzyl), acyl, or sulfonyl, e.g. allylsulfonyl, phthalimide, or tosyl; subsequent removal of the protecting group being effected when desired by hydrolysis or hydrogenolysis as appropriate using standard conditions. Hydroxyl and carboxyl groups may be

15 protected using any conventional hydroxyl or carboxyl protecting group. Examples of suitable hydroxyl and carboxyl protecting groups include groups selected from alkyl, e.g. methyl, tert-butyl or methoxymethyl, arylmethyl e.g. benzyl, diphenylmethyl, or triphenylmethyl, heterocyclic groups such as tetrahydropyranyl, acyl e.g. acetyl or benzoyl and silyl groups such as trialkylsilyl, e.g. tert-

20 butyldimethylsilyl. The hydroxyl protecting groups may be removed by conventional techniques. Thus, for example, alkyl, silyl acyl, and heterocyclic groups may be removed by hydrolysis under acidic or basic conditions. Arylmethyl groups such as triphenylmethyl may similarly be removed by hydrolysis under acidic conditions. Aralymethyl groups such as benzyl may be cleaved by hydrogenolysis in the 25 presence of a Nobel metal catalyst such as palladium-on-charcoal. Silyl groups may also conveniently be removed using a source of fluoride ions such as tetra-n-butylammonium fluororide.

According to a first general process A, compounds of formula (I) may be prepared
30 by the reaction of an amine of formula (III) wherein R¹, R², R³, X and z have the meanings defined in formula (I)

15



with a compound $R^{11}Y$ (IV) wherein Y is the group -NCO, HNCOCl or $NHCOR_a$ where R'_a is nitro substituted phenoxy group or a 1-imidazole group.


5

The reaction conveniently takes place in the presence of a suitable solvent such as a halohydrocarbon (e.g. dichloromethane), an ether (e.g. tetrahydrofuran) or nitrile (e.g. acetonitrile) or a mixture thereof at a temperature in the range of 0^0 - 80^0 C.

- 10 Compounds of formula (IV) wherein Y is -NCO may be purchased or prepared by the reaction of amines H_2N-R^{11} with phosgene or triphosgene in a suitable solvent such as methylene chloride. Compounds of formula (IV) wherein Y is HNCOCl are also prepared by the reaction of amines H_2NR^{11} with phosgene or triphosgene in a suitable solvent such as methylene chloride. Compounds of formula (IV) wherein Y
- 15 is $NHCOR_a$ and R_a is a 1-imidazole group are prepared by treatment of amines H_2N-R^{11} with carbonyl diimidazole in a suitable solvent (dichloromethane, ether, tetrahydrofuran) at a temperature ranging from 0 - 80^0 C (conveniently at room temperature). Compounds of formula (IV) wherein Y is $HNCOR_a$ and R_a is a nitro substituted phenoxoy group are prepared by the reaction of amines H_2N-R^{11} with the
- 20 appropriate chloroformate R_aCOCl in the presence of a base (pyridine, triethylamine) in a suitable solvent (dichloromethane) and at a temperature of 0 - 50^0 C.


According to a further general process B, compounds of formula (I) may be
25 prepared by reaction of an intermediate of formula (V).

16



wherein Y is the group -NCO, -NHCOCl or NHCOR_a wherein R_a is a nitro substituted phenoxy group or a 1-imidazole group with an amine (VI)

5



and optionally in the presence of a base such as a tertiary amine (e.g. triethylamine).


10

The reaction conveniently takes place in a suitable solvent such as a halogenated hydrocarbon (e.g. dichloromethane) or an ether (e.g. tetrahydrofuran) or an amide (e.g. N,N-dimethyl formamide) optionally at a temperature ranging from room temperature to the reflux temperature of the solvent.

15

Conveniently the compounds of formula (V) are prepared in situ from the amine (III).

In a particular aspect of the process (B) when Y is the group NHCOR_a and R_a is a 1-imidazole group, the imidazolidine (V) may be formed in situ in which case the 20 amine of formula (VI) will be mixed with the compound of formula (III)




in the presence of carbonyldiimidazole under the aforementioned conditions.

For process B when Y is the group NHCOR_a and R_a is a nitro substituted phenoxy group the reaction with the primary amine (VI) is preferably carried out in the presence of a base such as a tertiary amine e.g. triethylamine.

- 5 For process B when Y is the isocyanate group $-\text{N}=\text{C}=\text{O}$ the reaction with the primary amine (VI) is preferably carried out in an aprotic solvent such as a halohydrocarbon e.g. methylene chloride. Conveniently the isocyanate is generated in situ prior to the addition of the primary amine (VI).
- 10 The compounds of formula (V) wherein R_a is an optionally substituted phenoxy group may be prepared from the primary amine (III) by reaction with the corresponding nitro substituted phenyl chloroformate in the presence of a base such as pyridine. The reaction may be carried out in a solvent such as a halohydrocarbon e.g. dichloromethane and at a temperature from $0\text{--}50^\circ\text{C}$.
- 15 Compounds of formula (V) wherein R_a is a 1-imidazole group may be prepared by reacting a compound of formula (III) with carbonyldiimidazole in the presence of a suitable solvent such as a halogenated hydrocarbon (e.g. dichloromethane) or an ether (e.g. tetrahydrofuran) at a temperature ranging from 0°C to 80°C (conveniently at 20 room temperature).

Compounds of formula (V) wherein Y is the isocyanate grouping $-\text{N}=\text{C}=\text{O}$ or carbamoyl chloride $-\text{NHCOCl}$ may be prepared from the primary amine (III) by reaction with phosgene (COCl_2) or triphosgene in a suitable solvent such as 25 methylene chloride.

According to a further general process C compounds of formula (I) may also be prepared by a reaction of the compound of formula (VII)



with a haloacetamide having the formula (VIII)



5 wherein hal = Cl or Br.

The reaction is conveniently carried out by treating the compound of formula (VII) with a strong base such as sodium hydride in a polar aprotic solvent such as N,N-dimethylformamide followed by reaction with the acetyl halide (VIII).

10

The acetyl halide (VIII) is prepared by the reaction of the amine R¹-H with corresponding haloacetyl bromide in dichloromethane at 0°C, with a suitable base, such as triethylamine.

15

The amines R¹-H wherein R¹ is the group -NR⁴R⁵, may be prepared by the reductive alkylation of the amine H₂N-R⁵ with an appropriate aldehyde or ketone.

According to general process D, compounds of general Formula (I) may also be prepared by the reaction of the intermediate of Formula (III) with acids of Formula 20 (IX), as set forth below.



Thus reaction of the intermediates of formula (III) with the acid of formula (IX) may 25 be carried out in the presence of a suitable dehydrating agent such as dicyclohexylcarbodiimide (DCC), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) or 4-benzotriazol-1-yloxytris-(dimethylamino)phosphonium hexafluorophosphate (BOP, particularly in the presence of a suitable alcohol (N-hydroxysuccinimide or N-hydroxybenzotriazole).

30


Alternatively, compounds of general Formula (I) may be obtained by reaction of the intermediates of Formula (III) with an activated derivative of the acid (IX) such as an acid chloride or anhydride thereof, including mixed anhydrides.

Preferred solvents for general process D include N,N-dimethylformamide or dichloromethane. Preferred temperatures are between 0-60°C. Preferred bases for this reaction include triethylamine N-methylmorpholine or N,N-dimethylaminopyrine (DAMP).

- 5 According to a further general process (E) compounds of formula (I) may be prepared by reaction of a compound corresponding to a compound of formula (I) wherein R³ represents hydrogen with the halide R³ hal (wherein hal is Cl or Br and R³ is a group as defined in formula (I) and more particular a heteroaryl group e.g. pyridyl, pyrimidinyl etc). The reaction is conveniently carried out in the presence of
- 10 copper metal and potassium acetate and in the presence of a solvent such as dimethylsulphoxide or N,N-dimethylformamide and preferably the reaction is carried out at a temperature within the range 25-100°C.

- According to a further general process (F) compounds of the invention may be converted into other compounds of the invention. Thus for example compounds of formula (I) wherein R⁸ is the group (CH₂)_bCO₂H may be prepared by reaction of a compound of formula (I) wherein R⁸ is hydrogen with compound Br(CH₂)_bCOOR* wherein R* is C₁₋₄alkyl in the presence of a strong base such as sodium hydride followed by removal of the carboxy protecting group by conventional procedures
- 20 e.g. acidic or basic hydrolysis

- Also compounds of formula (I) in which R¹¹ is phenyl substituted by an alkoxy carbonyl group may be hydrolysed by conventional means, e.g. acid hydrolysis to give a compound of formula (I) in which R¹¹ is phenyl substituted by carboxy.
- 25 Compounds of formula (III) may be prepared by reduction of compounds of formula (X)



wherein W is CH-N₃ or C=N-NHPh.


Compounds of formula (X) wherein W is CH-N₃ may be reduced to a compound of formula (III) by hydrogenation in the presence of a suitable catalyst such as 5-10% palladium on a support such as carbon or calcium carbonate, or platinum (IV) oxide. The reaction conveniently takes place in the presence of a solvent such as an alkanol (e.g. ethanol) an ester (e.g. ethyl acetate) or acetic acid.

Compounds of formula (X) wherein W is C=N-NHPh may be reduced to a compound of formula (III) by reaction with zinc and acetic acid. This reaction may be carried out at a temperature in the range 0-50°.

Compounds of formula (X) wherein W is CHN₃ may be prepared from a compound of formula (X) wherein W is CH₂ by treatment with a strong base such as sodium hydride or potassium hexamethyl disilazide or potassium tert-butoxide followed by tri-isopropyl benzenesulphonyl azide or di-tertbutoxyazidodicarboxylate. The reaction conveniently takes place in a solvent such as an ether (e.g. tetrahydrofuran) at a temperature in the range of -78° to 20°.

Compounds of formula (III) may also be prepared by reaction of a compound of formula (X) wherein W is CH₂ with a suitable base such as sodium bis(trimethylsilyl) amide and O-(diphenyl-phosphenyl) hydroxylamine in a solvent such as dimethyl formamide.


Compounds of formula (X) in which W is C=NNHPh or CH₂ may be prepared by reaction of the ortho-phenylenediamine (XI) with the diacid chloride (XII) wherein Q is CH₂ or C=NNHPh, in a suitable solvent such as an ether e.g. tetrahydrofuran



The compound of formula (XII) wherein Q is C = NNHPh may be prepared by reaction of ketomalonic acid with phenyl hydrazone followed by reaction with phosphorus pentachloride.

Compounds of formula (XI) are either known compounds or may be prepared by analogous methods. Thus for example a compound of formula (XI) may be prepared by alkylation of the amine (XIII).

10




Thus the amine (XIII) may be reacted with the compound $R_1COCH_2\text{hal}$ wherein hal is chlorine or bromine, optionally in the presence of sodium iodide in a solvent such as N,N-dimethylformamide and a base such as potassium carbonate.

15


An alternative preparation of the intermediate of Formula (III) as set forth below, involves treatment of the intermediate of Formula (XIV) with sodium hydride followed by addition of a haloacetamide (VIII) in a suitable solvent, such as N,N-dimethyl formamide, at 0°C to provide the protected intermediate of Formula (XV)

20

22



(XIV)




(XV)

Intermediate (XVI) may be converted to amine (III) by treatment with HBr in methylene chloride.

5


Intermediate (XIV) is obtained from the intermediate of Formula (XVI) by reaction with benzyloxymchloroformate in dichloromethane, using triethylamine as base. This reaction is run conveniently at room temperature.



10


Intermediate (XVI) is prepared from phenylene diamine (XIII) by the following process.

Reaction of the diamine (XIII) with p-methoxybenzoylchloride followed by reduction of the amide thus formed with lithium aluminum hydride yields the N-protected diamine (XVII)



5

Reaction of compound (XVII) with the diacid chloride (XII; Q = C=NNHPh) followed by reduction with zinc and acetic acid yields the amine (XVIII)



10

The compound of formula (XVIII) may be converted into the required compound (XVI) by reaction with Ce(NO2)6NH4 (ceric ammonium nitrate).


Compounds of formula (VII) may be prepared from a compound of formula (XVI)
15 using the general processes A, B or C. described above.

Compounds corresponding to those of formula (I) but wherein R³ represents hydrogen may be prepared from the corresponding amine (III) wherein R³ represents hydrogen using the general processes A, B and C. Compounds of
20 formula (III) wherein R³ is hydrogen may be prepared using the general processes described above for preparing compounds of formula (III) wherein R³ is a


heterocyclic group but using intermediates wherein R³ is a p-methoxybenzyl group which can then be removed in a conventional manner.

Thus reaction of the diamine (XIX)

5




with the haloacetamide (VIII) yields the disubstituted diamine (XX)



10


Reaction of compound (XX) with the diacid chloride (XII) wherein Q is C=NNHPh, followed by reduction with zinc and acetic acid yields the benzodiazepine (XIX)



15


Reaction of the compound of formula (XXI) with ceric ammonium nitrate yields the compound corresponding to that of formula (III) wherein R³ is hydrogen.

The diamine (XIX) may be prepared by reaction of the nitro fluoro derivative (XXII)



5 with p-methoxybenzylamine followed by reduction of the nitro group.


Compounds of formula (X) wherein W is CH₂ may be prepared by reaction of the compound of formula (XXIII) wherein X, z and R¹ have the meanings defined in
10 formula (I)



With the bromide R³ Br (wherein R₃ has the meaning defined above) in the
15 presence of copper dust and potassium acetate. The reaction is preferably carried out in a polar solvent such as dimethylformamide and with heating.

The compound (XXIII) may be prepared by reaction of the diamine (XXIV) wherein X₁, z and R¹ have the meanings defined above.

20



with malonyl dichloride in a similar matter to that described for the preparation of a compound of formula (X) wherein W is CH₂.

25 Compounds of formula (I) contain at least one asymmetric carbon atom, namely the carbon atom of the diazepine ring to which the substituted urea grouping is

attached. Specific enantiomers of the compounds of formula (I) may be obtained by resolution of the racemic compound using conventional procedures such as chiral HPLC. Alternatively the required enantiomer may be prepared from the corresponding enantiomeric amine of formula (III) using any of the processes 5 described above for preparing compounds of formula (I) from the amine (III). The enantiomers of the amine (III) may be prepared from the racemic amine (II) using conventional procedures such as salt formation with a suitably optically active acid or by preparative chiral HPLC.

10

EXAMPLES

The following examples are set forth to illustrate the synthesis of some particular compounds of the present invention and to further exemplify particular applications 15 of general process A-E. Accordingly, the following Example section is in no way intended to limit the scope of the invention contemplated herein.

As used herein the symbols and conventions used in these processes, schemes and examples are consistant with those used in the contemporary scientific 20 literature, for example, the Journal of the American Chemical Society. Unless otherwise noted, all starting materials were obtained from commercial suppliers and used without further purification. Specifically, the following abbreviations may be used in the examples and throughout the specification: g (grams); mg (milligrams); L (liters); mL (milliliters); psi (pounds per square inch); M (molar); mM (millimolar); i. v. 25 (intravenous); Hz (Hertz); mol (moles); RT (room temperature); min (minutes); h (hours); M.p. (melting point); TLC (thin layer chromatography); MeOH (methanol); TFA (trifluoroacetic acid); THF (tetrahydrofuran); dimethylsulfoxide (DMSO); EtOAc (ethyl acetate); dichloromethane (DCM); dimethylformamide (DMF); 1, 1-carbonyldiimidazole (CDI); isobutylchloroformate (iBuCF); N-hydroxysuccinimide 30 (HOSu); N-hydroxybenztriazole (HOBT); 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC); bis(2-oxo-3-oxazolidinyl) phosphinic chloride (BOP); tert-butyloxycarbonyl (BOC); dicyclohexylcarbodiimide (DCC); benzyloxycarbonyl (Cbz). DMAP 4-dimethylaminopyridine. All references to ether are to diethyl ether. Unless otherwise indicated, all temperatures are expressed in °

C (degrees Centigrade). All reactions conducted at room temperature unless otherwise noted.

The ^1H NMR spectra were recorded on either a Varian VXR-300 or a Varian Unity-
5 300 instrument. Chemical shifts are expressed in parts per million (ppm, d units). Coupling constants are in units of hertz (Hz). Splitting patterns are designated as s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; b, broad.

Low-resolution mass spectra (MS) were recorded on a JOEL JMS-AX505HA, JOEL
10 SX-102 or a SCIEX-APlili spectrometers. All mass spectra were taken in the positive ion mode under electrospray ionization (ESI), chemical ionization (CI), electron impact (EI) or by fast atom bombardment (FAB) methods. Infrared (IR) spectra were obtained on a Nicolet 510 FT-IR spectrometer using a 1-mm NaCl cell. Rotations were recorded on a Perkin-Elmer 241 polarimeter. All reactions were
15 monitored by thin-layer chromatography on 0.25 mm E. Merck silica gel plates (60F-254), visualized with UV light, 7% ethanolic phosphomolybdic acid or p-anisaldehyde solution. Flash column chromatography was performed on silica gel (230-400 mesh, Merck).

20 Products were purified by preparative reversed phase high pressure liquid chromatography (RP-HPLC) using a Waters Model 3000 Delta Prep equipped with a Delta-pak radial compression cartridge (C18, 300 A, 15m, 47 mm X 300 mm). Solvent systems included A, aqueous 0.1% trifluoroacetic acid, B, 60% acetonitrile, 40% aqueous 0.1% trifluoroacetic acid and C, acetonitrile. All solvents contained
25 0.1% TFA. Linear gradients were used in all cases and the flow rate was 100 mL/minute ($t_0 = 5.0$ min.). Analytical purity was assessed by RP-HPLC using a Waters 600E system equipped with a Waters 990 diode array spectrometer (λ range 200-400 nM). The stationary phase was a Vydac C18 column (5m, 4.6 mm X 250 mm). The flow rate was 1.0 to 1.5 ml/min. ($t_0 = 2.8$ or 3.0 min.) and the solvent
30 systems were as described above. Data reported as tr, retention time in minutes (% acetonitrile over time).

Example 1

2-[2,4-Dioxo-3-(3-phenyl-ureido)-5-pyridin-2-yl-2,3,4,5-tetrahydro-
35 benzo[b][1,4]diazepin-1-yl]-N-isopropyl-N-(4-methoxy-phenyl)-acetamide

A solution of phenyl isocyanate (25.6 mg) in methylene chloride (1 ml) was added to a solution of 2-(3-Amino-2,4-dioxo-5-pyrdin-2-yl-2,3,4,5-tetrahydrobenzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxy-phenyl)-acetamide (100mg) in 5 methylene chloride (1 ml) and the resultant mixture was stirred at rt for 4h. The solvents were removed *in vacuo* and the residue was recrystallised from ethyl acetate to afford the title product (44 mg) as an off-white solid. ^1H NMR (300 MHz, CDCl_3): 1.03 (2 x d, $J = 7\text{Hz}$, 6H), 3.81 (s, 3H), 4.17 (d $J = 16\text{Hz}$, 1H), 4.37 (d, $J = 16\text{ Hz}$, 1H), 5.0 (sept, $J = 7.1\text{ Hz}$, 1H), 5.40 (d, $J = 6.3\text{ Hz}$, 1H), 6.40 (d, $J = 5.3\text{ Hz}$, 1H), 6.8-7.3 (m, 17H), 7.80 (br, 1H), 8.42 (d, $J = 3.9\text{Hz}$, 1H).Tlc (10% MeOH, 10 CH_2Cl_2) $R_f = 0.53$. m/z [MH] $^+ = 593$.

Example 2

1H-Indole-2-carboxylic acid {1-[Isopropyl-(4-methoxy-phenyl)-carbamoylmethyl]-2,4-dioxo-5-pyrdin-2-yl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl}-amide

A solution of 2-(3-Amino-2,4-dioxo-5-pyrdin-2-yl-2,3,4,5-tetrahydrobenzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxy-phenyl)-acetamide (276mg), BOP (244 mg), HOBT (78 mg), DMAP (69 mg) and indole-2-carboxylic acid (98 mg) 20 in DMF (1ml) was stirred at rt for 18h. The reaction mixture was diluted with ethyl acetate (15 ml), washed with 1N aqueous sodium hydroxide solution (2 x 15 ml), water (20 ml), brine (20 ml), dried (K_2CO_3) and concentrated *in vacuo* to afford the crude product. Purification by RP-HPLC utilizing a linear gradient (20% A, 80% B to 90% B, 10% C , 30 min) gave the title product (26.6 mg) as a white lyophile; $T_r = 25$ 21.3 min. ^1H NMR (300 MHz, CDCl_3): 0.98 (2 x d, $J = 7\text{Hz}$, 6H), 3.68 (s, 3H), 4.17 (d $J = 16.6\text{Hz}$, 1H), 4.37 (d, $J = 16.8\text{ Hz}$, 1H), 4.87 (sept, $J = 6.8\text{ Hz}$, 1H), 5.40 (d, $J = 6.8\text{ Hz}$, 1H), 6.40 (d, $J = 5.3\text{ Hz}$, 1H), 6.75-6.84 (m, 5H), 6.92-6.99 (m, 2H), 7.07 (t, $J = 7.3\text{ Hz}$, 1H), 7.09-7.2 (m, 4H), 7.24 (t, $J = 9.2\text{ Hz}$, 1H), 7.40 (t, $J = 9.1\text{ Hz}$, 2H), 7.52 (d $J = 7.9\text{ Hz}$, 1H), 7.72 (m, 2H), 8.38 (d, $J = 4.4\text{Hz}$, 1H), 9.19 (s, 1H). m/z 30 [MH] $^+ = 617$.

Examples 3 and 4

(+) or (-) 1H-Indole-2-carboxylic acid {1-[Isopropyl-(4-methoxy-phenyl)-carbamoylmethyl]-2,4-dioxo-5-pyridin-2-yl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl}-amide

A 100 mg portion of Example 2 was applied to a semipreparative Pirkle D-Leucine column and the individual enantiomers were eluted with an isocratic solvent system consisting of hexane (77%), isopropyl alcohol (20%) and acetonitrile (3%). Each 5 solvent contained 0.3% diethylamine. Appropriate fractions were collected and combined. The solvent was removed in vacuo and the residue was triturated with water. The resulting precipitate was separated by filtration and dried in vacuo.

Example 3: Chiral analytical (Pirkle D-Leucine, 2 mL/min) tr = 19.62 min (100%); m/z [MH]⁺ = 617

10 Example 4: Chiral analytical (Pirkle D-Leucine, 2 mL/min) tr = 22.797 min (98.4%); m/z [MH]⁺ = 617

Example 5

1H-Indole-2-carboxylic acid {1-[Isopropyl-(4-methoxy-phenyl)-carbamoylmethyl]-2,4-
15 dioxo-5-pyrimidin-2-yl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl}-amide

To a solution of 2-(3-Amino-2, 4-dioxo-5-pyrimidin-2-yl-2, 3, 4, 5-tetrahydro-benzo [b] [1, 4] diazepine-1-yl)-N-isopropyl-N-(4-methoxy-phenyl)-acetamide (933mg, 1.97mmol) in DMF (20mL) were added indole-2-carboxylic acid (333mg, 2.07mmol), 20 N-hydroxybenzotriazole (266mg, 1.97mmol), and 1-(3-dimethylaminopropyl)-3- ethylcarbodiimide hydrochloride (415mg, 2.16mmol) successively with stirring at ambient temperature. The resultant mixture was stirred at ambient temperature for 18 hours. The solvent was evaporated under reduced pressure to give a yellow oil which was dissolved in ethyl acetate (100mL), washed with water (2 x 30mL), dried 25 over MgSO₄, filtered and concentrated under reduced pressure to give a tan foam. The crude product was purified by flash chromatography on silica gel (30g) eluting with ethyl acetate (600mL). Appropriate fractions were combined and concentrated in vacuo to give the title compound (902mg, 1.46mmol) as a white foam: ¹H NMR (CDCl₃, 400MHz): 9.44 (s 1H), 8.75 (d, 2H, J=4.4Hz), 7.64-6.88 30 (m,15H), 5.60 (d, 1H, J=6.8Hz), 5.03 (m, 1H), 4.45 (d, 1H, J=16.6Hz), 3.99 (d, 1H, J=16.6Hz), 3.81 (s, 3H), 1.07 (m, 6H); TLC (CH₂Cl₂/CH₃OH (19:1)): R_f= 0.63; MS (FAB) m/z 618.2 (MH⁺).

Example 6

1H-Indole-2-carboxylic acid [1-isopropyl-(4-methoxy-phenyl)-carbamoylmethyl]-2,4-dioxo-5-(1,3,5-trimethyl-1H-pyrazol-4-yl)-2,3,4,5-tetrahydro-1H-benzo [b][1,4]diazepin-3-yl]-amide

5 To a solution of 2-[3-Amino-2,4-dioxo-5-(1,3,5-trimethyl-1H-pyrazol-4-yl)-2,3,4,5-tetrahydro-benzo [b][1,4] diazepin-1-yl]-N-isopropyl-N-(4-methoxy-phenyl)-acetamide (385mg, 0.76 mmol) in DCM (5 mL) was added indole-2-carboxylic acid (148mg, 0.92), HOBT (125mg, 0.92 mmol), EDC (176mg, 0.92 mmol), and TEA (2d). The solution stirred at RT for 48 h, then poured into DCM (100 mL). The mixture
10 was extracted with saturated sodium bicarbonate (x2), brine, dried over MgSO₄, and concentrated in vacuo. The resulting solid was triturated with ethanol to yield the
title compound (159mg): Tr= 18.3 min (30-55%C over 30 min); ¹HNMR (d₆-DMSO, 300 MHz) δ 11.8 (s, 1H), 8.45(s, 1H), 7.7-6.9 (m, 12H), 5.36 (m, 1H), 4.78 (m, 1H), 4.23 (m, 2H), 3.79 (s, 3H), 3.64 (d, 3H, J= 26.6), 2.11 (d, 3H, J= 31), 1.5 (d, 3H, J= 15 72); low resolution MS(FAB) m/e 648 (MH⁺).

Example 7

1H-Indole-2-carboxylic acid {1[isopropyl-(4-methoxy-phenyl)-carbamoylmethyl]-2,4-dioxo-5-pyridin-3-yl-2,3,4,5-tetrahydro-1H-benzo [b][1,4] diazepin-3-yl}-amide

20 To a solution of 1H-Indole-2-carboxylic acid {1-isopropyl-(4-methoxy-phenyl)-carbamoylmethyl]-2,4-dioxo-2,3,4,5-tetrahydro-1H-benzo [b][1,4] diazepine-3-yl}-amide (0.14g, 0.26 mmol) and 3-bromopyridine (40μL, 0.42 mmol) in DMF (1 mL) was added copper powder (46mg, 0.73 mmol) and acetic acid potassium salt (38mg, 25 0.73 mmol). The heterogenous solution was stirred at 100°C for 15 h and subsequently hot filtered through celite and washed with methanol. The resulting precipitate was filtered and purified by RPHPLC (40-60%C over 30 min) to yield the
title compound (19mg) as a white lyophile: Tr= 8.7 min (40-60%C over 30 min); ¹HNMR (d₆-Acetone, 300 MHz) δ 10.98 (s, 1H), 9.02 (s, 1H), 8.76 (s, 1H), 7.85 (d, 30 1H, J= 8.8), 7.5 (m, 15H), 5.68 (d, 1H, J= 7.6), 5.02 (m, 1H), 4.65 (ABq, 2H, J= 16.8, 135), 4.02 (s, 3H), 2.19 (d, 3H, J= 2.0), 2.18 (d, 3H, J= 2.0); low resolution MS(FAB) m/e 617 (MH⁺).

Example 8

2-[2,4-dioxo-3-(3-phenyl-ureido)-5-pyridin-3-yl-2,3,4,5-tetrahydrobenzo[b][1,4]diazepin-1-yl]-N-isopropyl-N-(4-methoxy-phenyl) acetamide

A solution of phenyl isocyanate (36.6 mg, 0.295 mmol) in methylene chloride (1 ml) 5 was added to a solution of 2-(3-Amino-2,4-dioxo-5-pyridin-3-yl-2,3,4,5-tetrahydrobenzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxy-phenyl) acetamide (140 mg, 0.295 mmol) in methylene chloride (1 ml) and the resultant solution stirred at rt for 16h. The solvent was removed in vacuo and the residue recrystallised from 10 5% methanol in ethyl acetate to afford the title compound product (49 mg) as a white powder. ^1H NMR (300 MHz, CDCl-3). s 8.72 (s, 1H), 8.56 (d, 1H, J = 8.0), 7.92 (d, 1H, J = 8.0), 6.91-7.43 (m, 16H), 6.43 (d, 1H, J = 8.3), 5.43 (d, 1H, J = 8.3), 4.95 (sept, 1H, J = 6.8), 4.60 (d, 1H, J = 11.8), 4.18 (d, 1H, J = 11.8), 3.88 (s, 3H), 1.06 (m, 6H). Low resolution MS (FAB) m/e 593 (m+).

15

Example 9

3-(3-[1-isopropyl-(4-methoxy-phenyl)-carbamoylmethyl]-2,4-dioxo-5-pyridin-3-yl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-ureido)-benzoic acid tert butyl ester.

Triphosgene (22.1 mg) was added to a 0°C solution of t-butyl m-aminobenzoate 20 (43.3 mg, 0.224 mmol) in THF (5 ml) and triethylamine (0.068 ml) and the resultant mixture stirred at 0°C for 1h prior to the addition of 2-(3-Amino-2,4-dioxo-5-pyridin-3-yl-2,3,4,5-tetrahydrobenzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxy-phenyl) acetamide (106 mg, 0.224 mmol) and the resultant mixture stirred at rt overnight.

The solvent was removed in vacuo and the residue dissolved in ethyl acetate (50 25 ml) and washed with 0.5N hydrochloric acid (2 x 30 ml), water (30 ml), brine (30 ml), dried (MgSO_4) and concentrated in vacuo to afford the title compound (115 mg) as a white solid. ^1H NMR (300 MHz, CDCl-3). s 8.62 (s, 1H), 8.59 (d, 1H, J = 8.0), 7.92 (d, 1H, J = 8.0), 6.91-7.83 (m, 15H), 6.43 (d, 1H, J = 8.1), 5.43 (d, 1H, J = 8.1), 4.91 (sept, 1H, J = 6.8), 4.60 (d, 1H, J = 11.8), 4.18 (d, 1H, J = 11.8), 3.86 (s, 3H), 1.66 (s, 9H), 1.06 (m, 6H).

Example 10

3-(3-[1-isopropyl-(4-methoxy-phenyl)-carbamoylmethyl]-2,4-dioxo-5-pyridin-3-yl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-ureido)-benzoic acid

A mixture of 3-(3-{1-[isopropyl-(4-methoxy-phenyl)-carbamoylmethyl]-2,4-dioxo-5-pyridin-3-yl}-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-ureido)-benzoic acid tert butyl ester (115 mg, 0.224 mmol) and 4N HCl in dioxane (1 ml) was stirred at rt for 1.75h after which time a further 1ml of 4N HCl in dioxane was added and the reaction mixture stirred at rt overnight. Ether (20 ml) was added and the resultant precipitate was triturated with ether (3 x 30 ml) to afford the title compound as a white powder.¹H NMR (300 MHz, CDCl₃).s 1H NMR (300 MHz, CDCl₃). s 8.61 (s, 1H), 8.56 (d, 1H, J = 8.2), 7.91 (d, 1H, J = 8.2), 6.91-7.83 (m, 16H), 6.41 (d, 1H, J = 7.9), 5.43 (d, 1H, J = 7.9), 4.91 (sept, 1H, J = 6.8), 4.60 (d, 1H, J = 11.8), 4.18 (d, 1H, J = 11.8), 3.86 (s, 3H), 1.06 (m, 6H). Low resolution MS (FAB) m/e 637 (m+).

Example 11

1H-Indole-2-carboxylic acid {1-[Isopropyl-(4-methoxy-phenyl)-carbamoylmethyl]-2,4-indole dioxo-5-pyridin-4-yl}-2,3,4,5,5a,9a-hexahydro-1H-benzo[b][1,4]diazepin-3-yl}-amide

To a solution of 23.3 mg (0.049 mmol) 2-(3-Amino-2,4-dioxo-5-pyridin-4-yl-2,3,4,5,5a,9a-hexahydro-benzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxy-phenyl)-acetamide in 0.5 mL DMF were added 8.5 mg (0.052 mmol; 1.05 equiv) indole-2-carboxylic acid, 6.7 mg (0.049 mmol; 1 equiv) N-hydroxybenzotriazole, and 10.4 mg (0.054 mmol; 1.1 equiv) 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride successively with stirring at ambient temperature. The resultant mixture was stirred at ambient temperature for 18 hours. The solvent was evaporated under reduced pressure to give a yellow oil which was taken into DCM (30 mL), washed with satd. NaHCO₃, dried over MgSO₄, filtered and concentrated under reduced pressure to a give a tan foam. The crude product was purified by flash chromatography on silica gel (4 g) eluted successively with ethyl acetate/hexanes (4:1; 100 mL), ethyl acetate (100 mL). Appropriate fractions were combined and concentrated in vacuo to give 10.2 mg (0.017 mmol) of the title compound as a white foam: ¹H NMR (Acetone-d₆, 300MHz) d 10.83 (s, 1H), 8.63 (s, 1H), 7.69 (m, 2H), 7.61 (d, 1H, J = 8.2), 7.53 (m, 3H), 7.45 (m, 1H), 7.38-7.28 (m, 4H), 7.23 (t, 1H), 7.09 (m, 4H), 5.50 (d, 1H, J = 7.6), 4.85 (m, 1H), 4.65 (d, 1H, J = 16.6), 4.28 (d, 1H, J = 16.7), 3.86 (s, 3H), 1.01 (m, 6H); TLC R_f= 0.36 (EtOAc); MS (FAB) m/z 617.3 (MH⁺).

Example 12

3-(3-[7-Fluoro-1-[isopropyl-(4-methoxy-phenyl)-carbamoylmethyl]-2,4-dioxo-5-pyridin-3-yl]-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-ureido)-benzoic acid
tert butyl ester

5

A solution of 84 mg of 2-(3-amino-7-fluoro-2,4-dioxo-5-pyridin-3-yl)-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxy-phenyl)-acetamide (0.165 mmol) in 4 mL of acetonitrile was combined with 59 mg of 3-[(4-nitrophenyl)oxycarbonyl]-amino-benzoic acid tert-butyl ester (0.165 mmol, 1 eq) and 10 heated at reflux under nitrogen for 3 hrs. The resulting slurry was cooled to 5 °C, held for 30 mins., filtered and dried under high vacuum to provide 93 mg of the title compound as a crystalline solid. ¹H NMR (300 MHz, d₆-DMSO) δ 9.41 (s, 1H), 8.74 (d, 1H, J = 2.3), 8.61 (dd, 1H, J = 1.5, 4.9), 7.99 (m, 1H), 7.95 (m, 1H), 7.67 (dd, 1H, J = 5.6, 9.3), 7.57 (m, 2H), 7.48 (m, 1H), 7.31 (m, 4H), 7.10 (d, 2H, J = 8.9), 6.97 (d, 1H, J = 7.7), 6.87 (dd, 1H, J = 8.9), 5.16 (s, 1H, J = 7.6), 4.78 (m, 1H), 4.56 (d, 1H, J = 16.5), 4.19 (d, 1H, J = 16.5), 3.84 (s, 3H), 1.54 (s, 9H), 0.98 (m, 6H); low resolution MS (FAB)m/e 710 (MH⁺).

Example 13

20 3-(3-[7-Fluoro-1-[isopropyl-(4-methoxy-phenyl)-carbamoylmethyl]-2,4-dioxo-5-pyridin-3-yl]-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-ureido)-benzoic acid.
A mixture of 84 mg of 3-(3-[7-fluoro-1-[isopropyl-(4-methoxy-phenyl)-carbamoylmethyl]-2,4-dioxo-5-pyridin-3-yl]-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-ureido)-benzoic acid tert butyl ester (0.118 mmol) and 4 mL of trifluoroacetic acid was stirred under nitrogen for 1.5 hrs. The trifluoroacetic acid was removed in vacuo and the residue was triturated with diethyl ether. The slurry was filtered, washed with diethyl ether and dried under high vacuum to provide 85 mg the title compound as a white crystalline trifluoroacetic acid salt. ¹H NMR (300 MHz, d₆-DMSO) δ 9.33 (s, 1H), 8.70 (b, 1H), 8.57 (d, 1H, J = 4.7), 8.00 (m, 1H), 7.97 (d, 1H, J = 8.6), 7.61 (dd, 1H, J = 5.5, 9.1), 7.55 (dd, 1H, J = 4.88, 8.2), 7.47 (m, 2H), 7.26 (m, 4H), 7.05 (d, 2H, J = 9.0), 6.92 (d, 1H, J = 7.8), 6.82 (dd, 1H, J = 2.8, 9.6), 5.10 (d, 1H, J = 7.6), 4.72 (m, 1H), 4.51 (d, 1H, J = 16.8), 4.14 (d, 1H, J = 16.8), 3.78 (s, 3H), 0.92 (m, 6H); low resolution MS (FAB)m/e 655 (MH⁺).

(+) or (-) 1H-Indole-2-carboxylic acid [1-[isopropyl-(4-methoxyphenyl)-carbamoylmethyl]-2,4-dioxo-5-pyridin-3-yl- 2, 3, 4, 5-tetrahydro -1H- benzo [b] [1,4] diazepin-3-yl] amide

5 Enantiomers of Example 7 were separated (>99.9%ee) by preparative high pressure liquid chromatography (HPLC) using a waters Model 4000 Delta Prep equipped with a Daicel Chemical Industries Chiralpak-AD preparative column (20 micron, 5 cm X 50 cm) as the stationary phase. The mobile phase employed was 72% hexane/ 21% isopropyl alcohol/ 7% chloroform. Isocratic conditions were used with a flow rate of 50 mL/min (to= 16 min). Appropriate fractions were combined, concentrated in vacuo, and lyophilized from water and acetonitrile to obtain the target analogs.

10 Analytical purity was assessed by HPLC using a Hewlett Packard 1050 system equipped with a Hewlett Packard 1050 diode array spectrometer (lambda range 200-400). The stationary phase was a Daicel Chemical Industries Chiralpak-AD (10 15 micron, 0.46 cm X 25 cm). The mobile phases were the same as above and the flow rate was 1.0 mL/min (to= 3 min). The retention time, tR, in minutes for the two isomers were as follows.

15 Enantiomer 1 Example 14: tR= 25.06 min.

Enantiomer 2, Example 15: tR= 81.39 min.

20

Intermediate 1

Isopropyl-(4-methoxyphenyl)amine

To a stirred solution of 4-methoxyphenylamine (1.24g, 6.22mmol) in methanol 25 (15mL) at ambient temperature was added successively, glacial acetic acid (415mg, 6.91mmol), acetone (669mg, 11.5mmol), and 1M sodium cyanoborohydride in THF (12.7mL, 12.6mmol). The reaction mixture was stirred overnight at room temperature. The pH was adjusted to 2 with 6N HCl and stirred for 30 minutes to quench excess sodium cyanoborohydride. The pH was then adjusted to 8.5 with 1N 30 NaOH and the resultant solution extracted with diethyl ether (2 x 50mL) and ethyl acetate (50mL). The organic extracts were combined, dried over sodium sulfate, filtered and concentrated under reduced pressure to give the title compound (1.42g, 5.91mmol) as a yellow oil. ¹H NMR (300MHz, CDCl₃): δ 6.78(d, J= 8.8Hz, 2H), 6.57(d, J= 9.1Hz, 2H), 3.75(s, 3H), 3.55(m, 1H), 2.92(br s, 1H), 1.18(d, J= 6.1Hz, 35 6H); TLC (EtOAc/Hex (2:3)): R_f= 0.72

Intermediate 2

2-Bromo-N-isopropyl-N-(4-methoxyphenyl) acetamide

5 To a solution of isopropyl-(4-methoxyphenyl)-amine (25.11g, 152mmol) in dichloromethane (250mL) was added triethylamine (15.38g, 152mmol) with stirring at ambient temperature. The solution was cooled in an ice bath (<3°C) and bromoacetyl bromide (30.68g, 152mmol) dissolved in dichloromethane (100mL) was added dropwise over a 45 minute period. The reaction mixture was stirred overnight
10 at ambient temperature, washed with 0.3N HCl (300mL) and brine (300mL), dried over sodium sulfate, filtered, and evaporated under reduced pressure to give a dark brown oil. The oil was filtered through a pad of silica gel (150g) which was eluted with ethyl acetate/hexane (1:1, 900mL) and the filtrate evaporated under reduced pressure to afford the title compound (41.05g, 143mmol) as a brown oil which
15 crystallized on standing.

¹H NMR (300MHz, CDCl₃): d 1.04(d, J= 6.8Hz, 6H), 3.53(s, 2H), 3.84(s, 3H),
4.93(m, 1H), 6.93(d, J= 9.1Hz, 2H), 7.10(d, J= 9.1Hz, 3H)
TLC (EtOAc/Hexane(3:17)): R_f= 0.18

20

Intermediate 3

2-(phenylhydrazone)-malonic acid

To a vigorously stirred solution of ketomalonic acid monohydrate (29.33 g) in ethanol (140 mL) and water (300 mL) at ambient temperature was added
25 phenylhydrazine (23.3 g) dropwise over a 40 minute period. The resultant slurry was stirred overnight at ambient temperature. The solid was separated by filtration, washed sucessively with cold water (100 mL) and ethanol (25 mL) and air dried. Subsequent drying was performed at 75°C overnight in a vacuum oven to give the title compound as a yellow solid (42.38 g). ¹H (300MHz, DMSO-d₆): d 7.12(t,
30 1H), 7.35-7.48(m, 4H); m.p.: 155-157°C (dec).

Intermediate 4

2-(phenylhydrazone)-propanedioyl dichloride

To a stirred slurry of 2-(phenylhydrazone)-malonic acid (14.73 g), in chloroform (90mL) at 5°C was added phosphorous pentachloride (36.84 g) portionwise over a 20 minute period. After complete addition, the solution was warmed to room temperature and stirred one hour, then heated to reflux for three hours. The 5 solution was cooled in an ice bath and the resultant precipitate was separated by filtration, washed with cold hexane (50 mL.), and dried under vacuum overnight to give the title compound (13.4 g) as a bright yellow solid. ^1H (300MHz, DMSO-d₆): δ 7.12(t, 1H), 7.20-7.56(m, 4H); m.p.: 135-138°C (dec).

10

Intermediate 5**2-(2-Aminopyridyl)nitrobenzene**

Sodium hydride (60% in oil, 1.26g) was added to a 0°C solution of 2-aminopyridine (2.00g) in THF (10 ml) and the resultant mixture stirred at 0°C for 1h. A solution of 15 2-fluoronitrobenzene (2.21 ml) in THF (8 ml) was added dropwise and the resultant mixture allowed to attain rt overnight. Saturated aqueous sodium carbonate (10 ml) was added and the separated aqueous phase extracted into dichloromethane (3 x 10 ml). The combined organic extracts were washed with brine (20 ml), dried (MgSO₄) and concentrated *in vacuo*. Flash column chromatography (cyclohexane: 20 ethyl acetate; 3:1 as eluant) gave the title compound (2.23g) as an orange/red solid. ^1H NMR (300 MHz, CDCl₃): 6.83 (m, 3H), 7.42 (dt, J = 1,7 Hz, 1H), 7.40 (dt, J = 1,7 Hz, 1H), 8.08 (dd, J = 1,7 Hz, 1H), 8.21 (d, J = 1,1.5 Hz, 1H), 8.61 (dt, J = 1,7 Hz, 1H), 10.0 (s, 1H). Mp = 71°C.

25

Intermediate 6**N-(2-pyridyl)phenylene diamine**

2-(2-Aminopyridyl)nitrobenzene (2.14g) was dissolved in glacial acetic acid (45 ml) and iron filings (5.57g) were added and the resultant mixture stirred at rt for 72h 30 after which time the solids were removed by filtration through celite and the solvent removed by concentration *in vacuo*. Aqueous sodium carbonate (2M) solution was added adjust the pH of the solution to pH 8 and this mixture was then extracted into dichloromethane (3 x 30 ml). The combined organics were washed with brine (30 ml), dried (MgSO₄) and concentrated *in vacuo* to afford the title compound (1.68g) 35 as a beige solid. ^1H NMR (300 MHz, CDCl₃): 6.12 (br, 2H), 6.42 (d, J = 6 Hz, 1H),

6.68 (m, 1H), 6.78 (m, 3H), 7.008 (dt, $J = 1, 6.0$ Hz, 1H), 7.15 (dd, $J = 1, 5.8$ Hz, 1H),
7.42 (m, 1H), 8.15 (br, 1H). Tlc (cyclohexane : ethyl acetate; 1:1) $R_f = 0.2$

Intermediate 7

5 N-Isopropyl-N-(4-methoxy-phenyl)-2-[2-(pyridin-2-ylaminophenylamino)]-acetamide

A mixture of N-(2-pyridyl)phenylene diamine (2.00g), isopropyl-(4-methoxyphenyl)amine (3.08g) and potassium carbonate (1.50g) in DMF (30 ml) was stirred at rt for 22h. The solvents were removed *in vacuo* and the residue was 10 partitioned between ethyl acetate (50 ml) and water (3 x 30 ml). The organic phase was washed with brine (30 ml), dried ($MgSO_4$) and concentrated *in vacuo* to afford the crude title product as a brown solid. Two recrystallizations from ethyl acetate : hexane (1:1) gave the title compound as a fawn solid. 1H NMR (300 MHz, $CDCl_3$): 1.01 (d, $J = 7$ Hz, 6H), 3.4 (s, 2H), 3.83 (s, 3H), 4.98 (sept, $J = 7$ Hz), 6.08 (s 1H), 15 6.31 (d, $J = 8.5$ Hz, 1H), 6.42 (d, $J = 8.0$ Hz, 1H), 6.66 (m, 2H), 6.9-7.1 (m, 6H), 7.22 (d, $J = 8.0$ Hz 1H), 7.40 (t, $J = 6.5$ Hz, 1H), 8.18 (d, $J = 3.5$ Hz, 1H). Tlc (10% MeOH, CH_2Cl_2) $R_f = 0.42$.

Intermediate 8

20 2-[2,4-Dioxo-3(phenyl-hydrazone)-5-pyridin-2-yl]-2,3,4,5-tetrahydro-
benzo[b][1,4]diazepin-1-yl]-N-isopropyl-N-(4-methoxyphenyl)-acetamide

A solution of N-isopropyl-N-(4-methoxyphenyl)-2-[2-(pyridin-2-ylamino-phenylamino)]-acetamide (500 mg) in THF (20 ml) and 2-(phenylhydrazone)-25 propanediol dichloride (317 mg) in THF (20 ml) was added concurrently to a 0°C sample of THF (20 ml) and the resultant mixture was allowed to warm to rt overnight. The solvents were removed *in vacuo* and the residue was dissolved in ethyl acetate (50 ml) and washed with 2N aqueous sodium bicarbonate (2 x 30 ml), water, (30ml), brine (30 ml), dried ($MgSO_4$) and concentrated *in vacuo* to afford the 30 crude product. Flash column chromatography on silica gel, eluting with 10% methanol/methylene chloride, gave the title compound as a 3:2 mixture of hydrazones (460 mg). Due to the mixture of diastereomers, the 1H NMR data were not diagnostic. Tlc (10% MeOH, CH_2Cl_2) $R_f = 0.62$.

2-(3-Amino-2,4-dioxo-5-pyridin-2-yl-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxy-phenyl)-acetamide

A mixture of 2-[2,4-Dioxo-3(phenyl-hydrazone)-5-pyrdin-2-yl-2,3,4,5-tetrahydro-
5 benzo[b][1,4]diazepin-1-yl]-N-isopropyl-N-(4-methoxy-phenyl)-acetamide (460 mg),
zinc dust (430 mg) and acetic acid (5.6 ml) was stirred at rt for 3h. The solids were
removed by filtration through celite, the filtrate was concentrated *in vacuo* and the
residue azeotroped with hexane. The residue was dissolved in ethyl acetate (50 ml)
and washed with 2N aqueous sodium bicarbonate (2 x 30 ml), water, (30ml), brine
10 (30 ml), dried ($MgSO_4$) and concentrated *in vacuo* to afford the crude product (270
mg) which was used without further purification. 1H NMR (300 MHz, $CDCl_3$): 1.03
(d, $J = 7$ Hz, 6H), 3.79 (s, 3H), 4.02 (d $J = 10$ Hz, 1H), 4.40 (s, 1H), 4.42 (d, $J = 10$
Hz, 1H), 5.0 (sept, $J = 7.1$ Hz, 1H), 6.8-7.3 (m, 10H), 7.44 (d, $J = 8.0$ Hz 1H), 7.68 (d,
 $J = 8.0$ Hz, 1H), 7.80 (m, 1H), 8.42 (d, $J = 3.9$ Hz, 1H). TLC (10% MeOH, CH_2Cl_2) R_f =
15 0.23.

Intermediate 10
(2-Nitro-phenyl)-pyrimidin-2-yl-amine

20 To a solution of 2-aminopyrimidine (10g, 105mmol) in DMF (100mL) cooled to 5°C
was added 60% sodium hydride in mineral oil (5.47g, 137mmol) and the resulting
mixture was stirred one hour with cooling. 1-fluoro-2-nitrobenzene (14.83g,
105mmol) in DMF (30mL) was added dropwise over a 20 minute period to the
cooled, stirring solution. The solution was allowed to warm slowly to ambient
25 temperature and stirred 3 h. The product was precipitated with the addition of water
(300mL), separated by filtration, and dried to give the title compound (13.39g,
61.9mmol) as an orange solid: 1H NMR (Acetone- d_6 , 400MHz): 10.34 (br s, 1H),
9.00 (d, 1H, $J=8.6$ Hz), 8.60 (d, 2H, $J=4.8$ Hz), 8.23 (d, 1H, $J=8.4$ Hz), 7.74 (t, 1H),
7.17 (t, 1H), 7.06 (t, 1H); TLC (EtOAc/Hexanes (3:17)): R_f =0.27.

30

Intermediate 11
N-Pyrimidin-2-yl-benzene-1,2-diamine

To a solution of (2-nitrophenyl)-pyrimidin-2-yl-amine (13.2g, 61.1mmol) in a mixture
35 of EtOAc (450mL) and CH_3OH (350mL) was added Raney Nickle (16g (water wet))

and the reaction mixture hydrogenated under 1 atm hydrogen at ambient temperature for 3 h. The catalyst was separated by filtration and the filtrate concentrated in vacuo to a red-brown solid which upon trituration with cold CH₃OH (250mL) gave the title compound (8.21g, 44.1mmol) as a grey solid: ¹H NMR (CDCl₃, 400MHz): 8.38 (d, 2H, J=4.9Hz), 7.37 (d, 1H, J=7.9Hz), 7.08 (t, 1H), 7.00 (br s, 1H), 6.83 (m, 2H), 6.67 (t, 1H), 3.60 (br s, 2H); TLC (EtOAc/Hexanes(2:1)): R_f= 0.33.

Intermediate 12

10 N-Isopropyl-N-(4-methoxy-phenyl)-2-[2-(pyrimidin-2-ylamino)-phenylamino]-acetamide

To a solution of N-pyrimidin-2-yl-benzene-1,2-diamine (82mg, 0.441mmol) in DMF (2mL) was added potassium carbonate (61mg, 0.441mmol), potassium iodide (7mg, 0.044mmol), and 2-Bromo-N-isopropyl-N-(4-methoxy-phenyl)-acetamide (126mg, 0.441mmol). The resultant reaction mixture was stirred overnight at 60°C. The solvent was removed in vacuo and the crude material partitioned between CH₂Cl₂ (35mL) and water (15mL). The organic phase was separated, dried with MgSO₄, filtered and concentrated to a yellow oil which upon trituration with EtOH (6mL) and 15 filtration gave the title compound (96.7mg, 0.247mmol) as yellow crystals: ¹H NMR (CDCl₃, 300MHz): 8.36 (d, 2H, J=4.9Hz), 7.38 (dd, 1H, J=1.2, 7.8Hz), 7.06-6.90 (m, 6H), 6.75 (t, 1H), 6.66 (t, 1H), 6.36 (dd, 1H, J= 1.2, 7.8Hz), 4.97 (m, 1H), 3.87 (s, 3H), 3.43 (s, 2H), 1.04 (d, 6H, J=6.8Hz); TLC (EtOAc): R_f= 0.62; MS (FAB) m/z 20 392.0 (MH⁺).

25

Intermediate 13

2-[2,4-dioxo-3-(phenyl-hydrazone)-5-pyrimidin-2-yl]-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine-1-yl]-N-isopropyl-N-(4-methoxy-phenyl)-acetamide

30 To a slurry of N-isopropyl-N-(4-methoxy-phenyl)-2-[2-(pyrimidin-2-ylamino)-phenylamino]-acetamide (500mg, 1.28mmol) in THF (12mL) cooled in an ice bath was added of 2-(phenyl-hydrazone) propandiyl dichloride (344mg, 0.141mmol) in THF (6mL) dropwise over 5 minutes. After complete addition, the solution was allowed to warm to room temperature and stirred overnight. The solvent was 35 evaporated under reduced pressure and the resultant oil dissolved in ethyl acetate

(80mL), washed with saturated sodium bicarbonate solution, dried over MgSO₄, filtered and concentrated under reduced pressure to give a yellow oil. The crude product was purified by flash chromatography on silica gel (15g) eluting with EtOAc/Hexanes (2:1, 250mL). Appropriate fractions were combined and 5 concentrated to give the title compound (500mg, 0.886mmol) as a yellow foam: ¹H NMR (CDCl₃, 300MHz): 11.22 (s, 1H), 8.58 (m, 2H), 7.70-6.90 (m, 14H), 5.05 (m, 1H), 4.46 (m, 1H), 3.82 (m, 4H), 1.12 (m, 6H); TLC (EtOAc/Hexanes(2:1)): R_f= 0.21; MS (FAB) m/z 564.1 (MH⁺).

10

Intermediate 14

2-(3-Amino-2, 4-dioxo-5-pyrimidin-2-yl-2, 3, 4, 5-tetrahydro-benzo [b] [1, 4] diazepine-1-yl)-N-isopropyl-N-(4-methoxy-phenyl)-acetamide

To a stirred solution of 2-[2,4-dioxo-3-(phenyl-hydrazone)-5-pyrimidin-2-yl-2,3,4,5-15 tetrahydro-benzo[b][1,4]diazepine-1-yl]-N-isopropyl-N-(4-methoxy-phenyl)-acetamide (500mg, 0.886mmol) in acetic acid (12mL) at ambient temperature was added zinc dust (530mg) and the resulting mixture was stirred 1 h. The zinc was separated by filtration, the filtrate concentrated in vacuo, and the resultant oil partitioned between water (30mL) and ethyl acetate (80mL). The pH was adjusted 20 to 8 with 6N sodium hydroxide and the phases were separated. The aqueous phase was extracted with ethyl acetate (2 x 35mL) and the organics combined, dried with magnesium sulfate, filtered and concentrated in vacuo to give a yellow foam. The crude product was purified via flash chromatography on silica gel (15g) eluting with methylene chloride/methanol (19:1, 250ml). Appropriate fractions were combined 25 and concentrated to give the title compound (255mg, 0.537mmol) as a white glass: ¹H NMR (CDCl₃, 400MHz): 8.78 (d, 2H, 4.9Hz), 7.59 (dd, 1h, J= 1.1,8.3Hz), 7.33-7.25 (m, 3H), 7.16 (t, 1H), 7.05 (dd, 1H, J= 1.4,8.3Hz). 6.96 (dd, 1H, J= 2.7,8.7Hz), 6.89 (dd, 1H, J= 2.7, 8.5Hz), 6.86 (dd, 1H, J= 1.2,8.2Hz), 5.06 (m, 1H), 4.52 (d, 1H, J= 16.6Hz), 4.43 (s, 1H), 3.85 (d, 1H, J= 16.6Hz), 3.82 (s, 3H), 2.60 (br s, 2H), 1.11 30 (d, 6H, J=1.0Hz); TLC (CH₂Cl₂/CH₃OH (9:1)): R_f= 0.48; MS (FAB) m/z 475.3 (MH⁺).

Intermediate 15

(2-Nitrophenyl)-(1,3,5-trimethyl-1H-pyrazol-4-yl)-amine

To a solution of 1-fluoro-2-nitrobenzene (7.47mL, 70.9 mmol) in ethanol (35 mL) and H₂O (105 mL) was added 4-amino-1,3,5-trimethylpyrazole (8.8g, 70.9 mmol). The solution was refluxed for 15 h, then cooled to room temperature. The precipitate was separated by filtration and washed with 25% aqueous ethanol to yield the title compound (8.6g): ¹HNMR (CDCl₃, 300 MHz) δ 8.81 (s, 1H), 8.18 (dd, 2H, J=1.6, 8.7), 6.69(m, 1H) 6.61 (dd, 1H, J= 1.2, 8.7), 3.77 (s, 3H), 2.10 (s, 3H), 2.06 (s, 3H); low resolution MS(FAB) m/z 247(MH⁺).

Intermediate 16

10 N-(1,3,5-Trimethyl-1H-pyrazol-4-yl)-benzene-1,2-diamine

To a solution of (2-Nitro-phenyl)-(1,3,5-trimethyl-1H-pyrazol-4-yl)-amine (8.6g, 35 mmol) in ethyl acetate (175 mL) was added 10% palladium on carbon (1g). The solution was stirred under a hydrogen atmosphere (50 psi) for 15 h and 15 subsequently filtered through a bed of celite, washed with ethyl acetate., and concentrated in vacuo to yield the title compound (7.56g): ¹HNMR (CDCl₃, 300 MHz) δ 6.74 (m, 3H), 6.32 (d, 1H, J= 1.9, 7.2), 4.6 (s, 1H), 3.75 (s, 3H), 3.1 (s, 2H), 2.05 (m, 6H); low resolution MS(FAB) m/z 217 (MH⁺).

20 Intermediate 17

N-Isopropyl-N-(4-methoxy-phenyl)-2-[2-(1,3,5-trimethyl-1H-pyrazol-ylamino)-phenylamino]-acetamide

To a solution of N-(1,3,5-Trimethyl-1H-pyrazol-4-yl)-benzene-1,2-diamine (7.56g, 25 35.0 mmol) and 2-bromo-N-isopropyl-N-(4-methoxy-phenyl)-acetamide (7.18g, 38.5 mmol) in DMF (70 mL) was added potassium carbonate (14.5g, 105 mmol) and potassium iodide (581mg, 3.5 mmol). The solution was heated at 80°C for 15 h and subsequently poured into DCM (100 mL). The mixture was extracted with H₂O (x4), 1N HCl (x2) and brine, dried over MgSO₄ and concentrated in vacuo. The resulting 30 foam was purified by trituration with Et₂O to yield the title compound (11.9g): ¹HNMR (CDCl₃, 300 MHz) δ 8.08 (s, 1H), 7.07 (dd, 4H, J= 2.2, 6.6), 6.63 (m, 2H), 6.31 (m, 2H), 5.03 (m, 1H), 4.76 (s, 1H), 3.87 (s, 3H), 3.74 (s, 3H), 3.46 (s, 2H), 2.02 (m, 6H), 1.07 (d, 6H, J= 6.8); low resolution MS(FAB) m/z 422 (MH⁺).

35 Intermediate 18

2-[2,4-Dioxo-3-(phenyl-hydrazone)-5-(1,3,5-trimethyl-1H-pyrazol-4-yl)-2,3,4,5-tetrahydro-benzo [b][1,4] diazepin-1-yl]-N-isopropyl-N-(4-methoxy-phenyl)-acetamide

5 A solution of N-Isopropyl-N-(4-methoxy-phenyl)-2-[2-(1,3,5-trimethyl-1H-pyrazol-ylamino)-phenylamino]-acetamide (3.0g, 7.1 mmol) in THF (70 mL) and a solution of 2-(phenyl-hydrazone)-propanediol dichloride (1.75g, 7.1 mmol) in THF (70 mL) were simultaneously added to THF (35 mL) cooled to 0°C. The solution stirred at RT for 15 h and was subsequently concentrated in vacuo to yield the title compound

10 (8.1g) which was used without further purification.

Intermediate 19

2-[3-Amino-2,4-dioxo-5-(1,3,5-trimethyl-1H-pyrazol-4-yl)-2,3,4,5-tetrahydro-benzo [b][1,4] diazepin-1-yl]-N-isopropyl-N-(4-methoxy-phenyl)-acetamide

15 To a solution of 2-[2,4-Dioxo-3-(phenyl-hydrazone)-5-(1,3,5-trimethyl-1H-pyrazol-4-yl)-2,3,4,5-tetrahydro-benzo [b][1,4] diazepin-1-yl]-N-isopropyl-N-(4-methoxy-phenyl)-acetamide (4.6g, 7.74 mmol) in glacial acetic acid (45 mL) was added zinc dust (4.6g). The heterogenous solution stirred at RT for 15 h and subsequently

20 filtered through a bed of celite, washed with ethyl acetate and concentrated to dryness. The resulting oil was dissolved in ethyl acetate (200 mL) and extracted with saturated sodium bicarbonate (x3), brine, dried MgSO₄, and concentrated in vacuo. The resulting oil was purified by silica gel flash chromatography (5% methanol/DCM) to yield the title compound (385mg): ¹H NMR (CDCl₃, 300 MHz) δ

25 7.60-6.80 (m, 10H), 5.05 (m, 1H), 4.4(m, 1H), 3.82 (s, 3H), 3.74 (s, 3H), 3.62 (s, 2H), 2.24 (s, 3H), 1.20 (s, 3H), 1.09 (m, 6H); low resolution MS(FAB) m/z 505 (MH⁺).

Intermediate 20

4-methoxybenzyl)-(2-nitrophenyl)-amine

30 To 2-fluronitrobenzene (80.65 mL, 0.77 mmol) dissolved in ethanol (200 mL) and water (600 mL) was added 4-methoxybenzylamine (100 mL, 0.77 mmol). The reaction mixture was heated at 92 °C for 15h, cooled to room temperature, and the orange precipitate was separated by filtration. The precipitate was recrystallized

35 from ethanol:water 1/3, then dissolved in ethyl acetate, dried over MgSO₄, and

concentrated in vacuo to yield the title compound (117.88g): ^1H NMR (300 MHz, CDCl₃) δ 8.35 (bs, 1H), 8.18 (d, J= 8.5 Hz, 1H), 7.38 (dd, J= 7.3, 7.8 Hz, 1H), 7.27 (d, J= 8.5 Hz, 2H), 6.85 (m, 3H), 6.66 (dd, J= 7.3, 7.8 Hz, 1H), 4.47 (collapsed ABq, J= 4.9 Hz, 2H), 3.81 (s, 3H); low resolution MS(FAB) m/z 258.99 (MH⁺).

5

Intermediate 21

N-(4-methoxy-benzyl)-benzene-1,2-diamine

Zinc dust (50g) was added to 4-methoxybenzyl)-(2-nitrophenyl)-amine (50g, mmol) 10 in glacial acetic acid (500 mL) cooled to 15°C in a three-neck round bottom fitted with an overhead stirrer. The reaction mixture was warmed to room temperature and stirred 15h. The reaction mixture was filtered through a pad of celite, and the filtrate was concentrated to dryness. The resulting oil was taken up in ethyl acetate/water and the pH of the aqueous layer was adjusted to 8 with sodium bicarbonate. The aqueous layer was extracted with ethyl acetate (x4), dried over MgSO₄ and concentrated in vacuo. The crude product was purified by silica gel flash chromatography (50% hexane/DCM) to yield the title compound (33.34g): ^1H NMR (300 MHz, CDCl₃) δ 7.32 (d, J=8.5 Hz, 2H), 6.88 (d, J= 8.5 Hz, 2H), 6.97 (m, 4H), 4.25 (s, 2H), 3.81 (s, 3H); low resolution MS(FAB) m/z 476 (MH⁺)

15

Intermediate 22

N-Isopropyl-2-[2-(4-methoxy-benzylamino)-phenylamino]-N-(4-methoxy-phenyl)-acetamide.

20 To a solution of N-(4-methoxybenzyl)-benzene-1,2-diamine (2.42g, 10.6mmol) in DMF (40mL) was added potassium carbonate (1.47g, 10.6mmol), potassium iodide (176mg, 1.06mmol), and 2-Bromo-N-isopropyl-N-(4-methoxy-phenyl)-acetamide (3.03g, 10.6mmol). The resultant reaction mixture was stirred overnight at 60°C. The solvent was removed in vacuo and the crude material 25 dissolved in EtOAc (150mL), washed with water (2 x 50mL) and brine (50mL), dried with MgSO₄, filtered and concentrated to a brown oil. The precipitate which formed upon the addition of ether (70mL) was filtered to give the title compound (1.39g, 3.21mmol) as a yellow solid. The remaining filtrate was 30 concentrated under reduced pressure to a brown oil which was purified by flash chromatography on silica gel (40g) eluted with EtOAc/Hexanes (1:4, 900mL). 35

Appropriate fractions were combined and concentrated under reduced pressure to give a second crop of the title compound (1.86g, 4.29mmol) as a brown oil:
1H NMR (300MHz, CDCl₃): δ 7.30 (m, 2H), 7.05 (m, 2H), 6.95 (m, 2H), 6.88 (m, 2H), 6.73-6.61 (m, 3H), 6.28 (m, 1H), 5.01 (m, 1H), 4.23 (s, 2H), 3.87 (s, 5 3H), 3.80 (s, 3H), 3.40 (s, 2H), 1.07 (m, 6H); TLC (EtOAc/Hexanes (1:4)): R_f= 0.14.

Intermediate 23

10 N-Isopropyl-2-[5-(4-methoxy-benzyl)-2,4-dioxo-3-(phenyl-hydrazone)-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl]-N-(4-methoxy-phenyl)-acetamide.

To a solution of N-Isopropyl-2-[2-(4-methoxybenzylamino)-phenylamino]-N-(4-methoxy phenyl)-acetamide (3.25g, 7.51mmol) in THF (50mL) cooled in an ice bath (<5°C) was added 2-(phenyl-hydrazone) propandioyl dichloride (1.84g, 15 7.51mmol) in THF (50mL) dropwise over 20 minutes. After complete addition, the solution was allowed to warm to room temperature and stirred overnight. The solvent was evaporated under reduced pressure and the resultant oil was dissolved in ethyl acetate (300mL), washed with saturated sodium bicarbonate solution (100mL) and brine (50mL), dried over MgSO₄, filtered and 20 concentrated under reduced pressure to give the title compound (4.55g, 7.51mmol) as a yellow oil: 1H NMR (300MHz, CDCl₃): δ 11.46 (s, 0.5H), 10.69 (s, 0.5H), 7.56-6.95 (m, 15H), 6.77-6.66 (m, 2H), 5.34 (m, 1H), 5.05 (m, 1H), 4.79 (m, 1H), 4.34-4.08 (m, 2H), 3.86 (s, 2H), 3.74 (s, 3H), 3.72 (s, 3H), 1.11 (m, 6H); TLC (EtOAc/Hexanes(2:3)): R_f= 0.30.

25

Intermediate 24

2-[3-Amino-5-(4-methoxy-benzyl)-2,4-dioxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl]-N-isopropyl-N-(4-methoxy-phenyl)-acetamide.

30 To a stirred solution of N-Isopropyl-2-[5-(4-methoxy-benzyl)-2,4-dioxo-3-(phenyl-hydrazone)-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl]-N-(4-methoxy-phenyl)-acetamide (4.55g, 7.51mmol) in acetic acid (50mL) was added zinc dust (4.50g) and the resultant mixture was stirred 4 hours at ambient temperature. The zinc was separated by filtration, the filtrate was concentrated 35 in vacuo, and the resultant oil partitioned between water (150mL) and ethyl

acetate (250mL). The pH was adjusted to 8 with 6N sodium hydroxide and the phases separated. The aqueous phase was extracted with ethyl acetate (2 x 80mL) and the organics combined, dried with magnesium sulfate, filtered and concentrated in vacuo to a brown oil. The crude product was purified via flash chromatography on silica gel (70g) eluting successively with EtOAc/Hexanes (2:1, 500mL) and methylene chloride/methanol (19:1, 500mL). Appropriate fractions were combined and concentrated to give the title compound (2.85g, 5.52mmol) as a brown oil: ^1H NMR (300MHz, CDCl_3): δ 7.43 (d, $J=7.3\text{Hz}$, 1H), 7.30-7.19 (m, 4H), 7.05-6.90 (m, 5H), 6.59 (d, $J=8.8\text{Hz}$, 2H), 5.13 (d, $J=15.1\text{Hz}$, 1H), 5.00 (m, 1H), 4.86 (d, $J=15.1\text{Hz}$, 1H), 4.25 (s, 1H), 4.21 (d, $J=16.6\text{Hz}$, 1H), 3.85 (s, 3H), 3.69 (s, 3H), 3.48 (d, $J=16.6\text{Hz}$, 1H), 1.09 (m, 6H); TLC (CH₂Cl₂/CH₃OH (29:1)): R_f = 0.11.

Intermediate 25

15 2-(3-Amino-2,4-dioxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxy-phenyl)-acetamide.

To a stirred solution of 2-[3-Amino-5-(4-methoxybenzyl)-2,4-dioxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl]-N-isopropyl-N-(4-methoxyphenyl)-acetamide (2.63g, 5.09mmol) in acetonitrile/H₂O (9:1, 70mL) at ambient temperature was added ceric ammonium nitrate (10.05g, 18.3mmol) portionwise over one hour. The solution was stirred overnight at room temperature. The solution was concentrated in vacuo, chased with toluene (2 x 50mL) and the residue was extracted with CH₂Cl₂ (3 x 50mL), filtered and concentrated to an orange glass. The crude product was purified by flash chromatography on silica gel (100g) eluting successively with CH₂Cl₂/CH₃OH (15:1, 1.5L) and CH₂Cl₂/CH₃OH (10:1, 1.3L). Appropriate fractions were combined and concentrated under reduced pressure to give the title compound (1.97g, 4.97mmol) as a brown foam: ^1H NMR (300MHz, DMSO-d₆): δ 10.68 (br s, 1H), 7.39-6.98 (m, 8H), 5.75 (s, 1H), 4.76 (m, 1H), 4.16-3.92 (m, 4H), 3.77 (s, 3H), 3.15 (m, 2H), 0.97 (m, 6H); TLC (CH₂Cl₂/CH₃OH (13:1)): R_f = 0.21.

Intermediate 26

35 1H-Indole-2-carboxylic acid {1-[isopropyl-(4-methoxyphenyl)-carbamoylmethyl]-2,4-dioxo-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl}-amide.

To a solution of 2-(3-Amino-2,4-dioxo-2,3,4,5-tetrahydro-benzo[b][1,4]-diazepin-1-yl)-N-isopropyl-N-(4-methoxyphenyl)-acetamide (350mg, 0.883mmol) in DMF (10mL) were added indole-2-carboxylic acid (142mg, 0.883mmol), N-5 hydroxybenzotriazole (119mg, 0.883mmol), and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (169mg, 0.883mmol) successively with stirring. The resultant mixture was stirred at ambient temperature for 18 hours. The solvent was evaporated under reduced pressure to give a yellow oil which was dissolved in ethyl acetate (60mL), washed with water (20mL) and brine (20mL), 10 dried over MgSO₄, filtered and concentrated under reduced pressure to a yellow oil which solidified on standing. The crude product was triturated with boiling ethanol (20mL), cooled, filtered, and dried to give the title compound (169mg, 0.313mmol) as a yellow solid: ¹H NMR (300MHz, Acetone-d₆): δ 10.85 (br s, 1H), 9.83 (br s, 1H), 7.67 (m, 2H), 7.53 (m, 2H), 7.37-7.20 (m, 7H), 15 7.04 (m, 3H), 5.28 (d, J=7.5Hz, 1H), 4.87 (m, 1H), 4.31 (d, J=16.3Hz, 1H), 4.13 (d, J=16.6Hz, 1H), 3.83 (s, 3H), 1.02 (m, 6H); TLC (CH₂Cl₂/CH₃OH (19:1)): R_f= 0.24; MS (FAB): m/z=540 (MH⁺).

Intermediate 27

20 N-Isopropyl-N-(4-methoxy-phenyl)-2-phenylamino acetamide.

A mixture of N-Isopropyl-N-(4-methoxy-phenyl) bromoacetamide (257.6 g 924 mmol), 1,2-phenylene diamine (100 g, 924 mmol) and potassium carbonate (128 g, 924 mmol) in DMF (1200 ml) was stirred at 0° for 2h and then allowed to stir at rt for 25 20h. The reaction mixture was filtered through celite and the filtrate concentrated in vacuo. The resultant residue was dissolved in EtOAc (1200 ml), washed with water (3 x 200 ml), brine (200 ml), dried (MgSO₄) and concentrated in vacuo. After removal of about 70% of the solvent a precipitate formed which was removed by filtration and washed with cold EtOAc and dried to afford the title compound (67.1g) 30 as a beige solid. The combined filtrates were concentrated in vacuo to afford a dark oil (88g). Two Recrystallisations from ethanol afforded a second batch of the title compound as a beige solid (29.6 g). ¹H NMR (300 MHz, DMSO-d₆). s 7.22 (m, 2H), 7.05(m, 2H), 6.47 (m, 1H), 6.34 (m, 2H), 5.95 (m, 1H), 4.81 (sept., 1H, J = 6.8), 4.59 (dt, 1H, J = 27.2, 6.1), 4.4 (s, 2H), 3.77 (s, 3H), 3.30 (s, 2H), 0.96 (d, 6H, J = 6.8).

Intermediate 282-(2,4-dioxo-2,3,4,5-tetrahydrobenzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxy-phenyl) acetamide.

A solution of N-Isopropyl-N-(4-methoxy-phenyl)-2-phenylamino acetamide (20 g, 563.8 mmol) in THF (500 ml) and a solution of malonyl dichloride (6.2 ml, 63.8 mmol) in THF (500 ml) were added simultaneously over 40 min to THF (100 ml) and the resultant solution stirred at rt for 72h after which time a further 3.0 ml of malonyl dichloride was added. 5h later the solvents were removed in vacuo and the residue dissolved in methylene dichloride (300 ml) and washed with 2N aqueous sodium bicarbonate (2 x 200 ml). The combined organics were washed with water (2 x 200 ml), brine (200 ml), dried (MgSO_4) and concentrated in vacuo to afford the crude product (23.8g). This was then triturated extensively with ether and the resultant brown solid then purified by flash column chromatography eluting with 5% methanol in methylene chloride to afford the title compound (8.85 g) as a beige solid. ^1H NMR (300 MHz, CDCl_3). δ 7.7 (s, 1H), 7.4 (m, 1H), 6.90 - 7.3 (m, 7H), 4.97 (sept., 1H, $J = 6.8$), 4.4 (m, 1H), 3.81 (s, 3H), 3.78 (m, 1H), 3.40 (s, 2H), 1.06 (d, 6H, $J = 6.8$).

Intermediate 292-(2,4-dioxo-5-pyridin-3-yl-2,3,4,5-tetrahydrobenzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxy-phenyl) acetamide

20 A mixture of 2-(2,4-dioxo-2,3,4,5-tetrahydrobenzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxy-phenyl) acetamide (3.5 g 9.48 mmol), copper powder (1.09 g, 17.06 mmol) 3-bromopyridine (0.91 ml, 9.48 mmol) and potassium acetate (1.11 g, 11.37 mmol) in DMF (80 ml) was heated at 100° for 7h. A further 0.4 ml of 3-bromopyridine 25 was added and the resultant mixture stirred at 100° for a further 14h. Copper powder (1.09 g, 17.06 mmol) 3-bromopyridine (0.91 ml, 9.48 mmol) and potassium acetate (1.11 g, 11.37 mmol) were added and the reaction mixture heated to 110°C for 6h. The solids were removed by filtration and the filtrate concentrated in vacuo and the residue was partitioned between ethyl acetate (150 ml) and 10% aqueous 30 ammonium hydroxide solution (150 ml). The combined organics were washed with water (2 x 100 ml), brine (50 ml), dried (MgSO_4) and concentrated in vacuo to afford the crude product. This was triturated extensively with ether to afford the title compound (2.56g) as a cream solid. ^1H NMR (300 MHz, CDCl_3). δ 7.86 (d, 1H, $J = 8.1$), 7.01-7.43 (m, 10H), 6.92 (d, 1H, $J = 8.3$), 5.05 (sept, 1H, $J = 6.8$), 4.22 (m, 2H), 35 3.88 (s, 3H), 3.58 (dd, 2H, $J = 32.2, 12.0$), 1.06 (m, 6H).

Intermediate 302-(3-Azido-2,4-dioxo-5-pyridin-3-yl-2,3,4,5-tetrahydrobenzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxy-phenyl) acetamide

5 Potassium hexamethyl disilazide (0.5 M in toluene, 4.59 ml, 2.29 mmol) was added dropwise over seven minutes to a -78° solution of 2-(2,4-dioxo-5-pyridin-3-yl-2,3,4,5-tetrahydrobenzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxy-phenyl) acetamide (750 mg, 1.64 mmol) in THF (15 ml) and the resultant solution stirred at -78° for 17 min. 2,4,6-triisopropyl-benzenesulfonyl azide (632 mg, 2.05 mmol) was added and 10 the reaction mixture stirred at -78° for 4 min prior to the addition of acetic acid (0.235 ml) and the reaction mixture allowed to attain rt. The solvents were removed in vacuo to afford the crude product. This was purified by flash column chromatography eluting with 5% methanol in methylene chloride to afford the title compound (530 mg) as a colorless foam. 1H NMR (300 MHz, CDCl-3). s 7.96 (d, 1H, J = 8.0), 6.91-7.43 (m, 11H), 5.05 (sept, 1H, J = 6.8), 4.42 (d, 1H, J = 12.1), 15 4.38 (s, 1H), 4.22 (d, 1H, J = 12.1), 3.88 (s, 3H), 1.06 (m, 6H).

Intermediate 312-(3-Amino-2,4-dioxo-5-pyridin-3-yl-2,3,4,5-tetrahydrobenzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxy-phenyl) acetamide

20 A mixture of 2-(3-Azido-2,4-dioxo-5-pyridin-3-yl-2,3,4,5-tetrahydrobenzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxy-phenyl) acetamide (530 mg, 1.06 mmol) and 10% palladium on carbon (53 mg) was stirred in ethanol (50 ml) under an atmosphere of hydrogen for 9h. A further batch of palladium on 25 carbon was added (53 mg) and the resultant mixture stirred for a further 16h. The solids were removed by filtration through celite and the filtrate concentrated in vacuo to afford the title compound (520 mg) which was used without further purification. 1H NMR (300 MHz, CDCl-3). s 8.52 (m, 2H), 7.92 (d, 1H, J = 8.0), 6.91-7.43 (m, 11H), 5.05 (sept, 1H, J = 6.8), 4.42 - 4.22 (m, 3H), 3.88 (s, 3H), 1.06 (m, 30 6H).

Intermediate 322-(2,4-Dioxo-5-pyridin-4-yl-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxy-phenyl)-acetamide

To a stirring solution of 400 mg (1.08 mmol) of 1-[isopropyl-(4-methoxy-phenyl)-amino]-1,5-dihydro-benzo[b][1,4]diazepine-2,4-dione in 20 mL of DMF was added 212 mg (2.16 mmol, 2.0 equiv) of potassium acetate, 206 mg (3.25 mmol, 3.0 equiv) copper dust, and 245 mg (2.62 mmol, 2 equiv) of 4-bromopyridine. The resulting
5 solution was heated at 122°C for 7 h. The reaction mixture was filtered hot through a pad of celite, the pad was washed with 10 mL of methanol and the filtrate concentrated in vacuo. The residue was diluted with EtOAc (100 mL) and washed with 5% aq ammonium hydroxide (5 x 25 mL). The organic layer was separated, dried (MgSO₄) and the solvents removed in vacuo. Purification of the material by
10 silica gel flash chromatography using EtOAc/Hexanes/NH₄OH (80:20:1) as eluent followed by recrystallization from EtOH afforded 80 mg (16%) of the title compound:
1H NMR (Acetone-d₆, 300 MHz) δ 8.57 (d, 1H, J = 4.6), 7.46 (m, 3H), 7.31 (m, 4H),
6.97 (m, 3H), 4.86 (sept, 1H), 4.48 (d, 1H, J = 16.8), 4.21 (d, 1H, J = 16.8), 3.86 (s,
3H), 3.67 (d, 1H, J = 12.2), 3.22 (d, 1H, J = 12.2), 1.02 (m, 6H); low resolution MS
15 (FAB) m/z 459.2 (MH⁺).

Intermediate 33

2-(3-Amino-2,4-dioxo-5-pyridin-4-yl-2,3,4,5,5a,9a-hexahydro- benzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxy-phenyl)-acetamide

20 To a stirred solution of 80 mg (0.175 mmol) 2-(2,4-Dioxo-5-pyridin-4-yl-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxy-phenyl)-acetamide in 3 mL DMF was added 0.210 mL (0.209 mmol, 1.2 equiv) 1 N Sodium bis(trimethylsilyl)amide in THF at 0°C. After stirring 0.5 h, 62 mg (0.262 mmol; 1.5 equiv) O-(diphenyl-phosphinyl)hydroxylamine (Harger, J.C.S. Perkin I, 3284-3288 (1981)) was added and the reaction mixture stirred 16 h at ambient temperature. The reaction mixture was filtered and the filtrate concentrated in vacuo. The crude product was purified by flash chromatography on 5 g silica gel eluted successively with EtOAc (100 mL), DCM/CH₃OH (19:1, 100 mL). Appropriate fractions were
25 combined and concentrated in vacuo to give the title compound as a clear glass:
The reaction mixture was filtered and the filtrate concentrated in vacuo. The crude product was purified by flash chromatography on 5 g silica gel eluted successively with EtOAc (100 mL), DCM/CH₃OH (19:1, 100 mL). Appropriate fractions were combined and concentrated in vacuo to give the title compound as a clear glass:
30 low resolution MS (FAB) m/z 474.2 (MH⁺); TLC R_f= 0.31 (DCM/CH₃OH, 19:1)).

Intermediate 34

2-Amino-N-isopropyl-N-(4-methoxy-phenyl)-acetamide

A solution of 2.86 g of 2-bromo-N-isopropyl-N-(4-methoxy-phenyl)-acetamide (10 mmol) in 100 mL methanol was saturated with ammonia at 0° and left for 3 days at ambient temperature in a sealed flask. Methanol and ammonia were removed in vacuo and the residue was dissolved in 100 mL of chloroform and washed with 5 water (2x 50 mL). The organic layer was dried over anhydrous MgSO₄, filtered, concentrated in vacuo and dried under high vacuum to afford 2.7 g of the title compound as an oil. ¹H NMR (300 MHz, CDCl₃) δ 6.96 (m, 4H), 4.99 (m, 1H), 3.84 (s, 3H), 2.97 (s, 2H), 1.58 (s, 2H), 1.05 (d, 6H, J = 6.6); low resolution MS (ESI)m/e 223 (MH⁺).

10

Intermediate 352-(4-Fluoro-2-nitro-phenylamino)-N-isopropyl-N-(4-methoxy-phenyl)-acetamide

A mixture of 9.06 g of 2,5-difluoro-nitrobenzene (60 mmol) and 12.64 g of 2-amino-15 N-isopropyl-N-(4-methoxy-phenyl)-acetamide (60 mmol, 1.0 equiv) were combined in 225 mL of 2:1 ethanol/water and heated to reflux under nitrogen and stirred vigorously overnight (approx. 16 hrs.). The resulting slurry was cooled to ambient temperature, filtered and washed with 2:1 water/ethanol. The wet solid was dissolved in methylene chloride, dried over anhydrous sodium sulfate, and 20 evaporated in vacuo. The residue was triturated with hexane, filtered and washed with hexane. The product was dried under high vacuum to provide 9.32 g of the title compound as an orange solid. ¹H NMR (300 MHz, CDCl₃) δ 7.89 (dd, 1H, J = 3.1, 9.3), 7.12 (m, 3H), 6.99 (m, 2H), 6.35 (dd, 1H, J = 4.8, 9.2), 5.03 (m, 1H), 3.89 (s, 3H), 3.57 (s, 2H), 1.09 (d, 6H, J = 6.8); low resolution MS (ESI)m/e 362 (MH⁺).

25

Intermediate 362-(2-Amino-4-fluoro-phenylamino)-N-isopropyl-N-(4-methoxy-phenyl)-acetamide

A solution of 30 mL ethyl acetate, 175 mL ethanol, and 2.50 g of 2-(4-Fluoro-2-nitro-30 phenylamino)-N-isopropyl-N-(4-methoxy-phenyl)-acetamide (6.92 mmol) was combined with 0.25 g of palladium on carbon (10 wt%) and hydrogenated under a hydrogen balloon over 16 hrs. The reaction mixture was filtered and evaporated in vacuo to provide 1.91 g of the title compound as a solid. ¹H NMR (300 MHz, CDCl₃) δ 7.03 (m, 2H), 6.94 (m, 2H), 6.36 (m, 3H), 4.99 (m, 1H), 4.37 (b, 3H), 3.86 (s, 3H), 3.39 (s, 2H), 1.07 (d, 6H, J = 6.8); low resolution MS (FAB)m/e 332 (MH⁺).

Intermediate 372-(7-Fluoro-2,4-dioxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxy-phenyl)-acetamide

5 A solution of 1.724 g of 2-(2-amino-4-fluoro-phenylamino)-N-isopropyl-N-(4-methoxy-phenyl)-acetamide (5.20 mmol) in 15 mL of tetrahydrofuran was transferred to an addition funnel. A solution of 0.506 mL of malonyl dichloride (5.20 mmol, 1.0 equiv) in 15 mL tetrahydrofuran was transferred to a separate addition funnel. Each solution of each reagent was simultaneously added dropwise over 30 min. to 100
10 mL of tetrahydrofuran at ambient temperature under nitrogen with vigorous agitation. After stirring for 20 min. at ambient temperature, an additional 0.506 mL of malonyl dichloride (5.20 mmol, 0.1 equiv) was added in a single portion. The reaction was allowed to stir an additional 2.5 hrs. and then evaporated in vacuo to a residue. The residue was purified on flash grade silica gel with 1:3 ethyl
15 acetate/hexane followed by 3:1 ethyl acetate/hexane. The appropriate fractions were combined, evaporated in vacuo to a residue and triturated with hexane. The hexane was removed in vacuo and the residual solid was dried under high vacuum to provide 1.061 g of the title compound as a tan solid. ¹H NMR (300 MHz, CDCl₃) δ 8.14 (b, 1H), 7.45 (dd, 1H, J = 5.5, 9.2), 7.29 (m, 1H), 7.05 (m, 1H), 6.94 (m, 3H),
20 6.78 (m, 1H), 4.99 (m, 1H), 4.37 (d, 1H, J = 16.4), 3.82 (s, 3H), 3.69 (d, 1H, J = 16.0), 3.40 (m, 2H), 1.09 (d, 6H, J = 6.8); low resolution MS (FAB)m/e 400 (MH⁺).

Intermediate 382-(7-Fluoro-2,4-dioxo-5-pyridin-3-yl-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxy-phenyl)-acetamide

25 A mixture of 0.880 g of 2-(7-Fluoro-2,4-dioxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxy-phenyl)-acetamide (2.20 mmol), 420 mg of copper (bronze, 6.61 mmol, 3 equiv), 476 mg of potassium acetate (4.85 mmol, 2.2 equiv), and 0.290 mL of 3-bromopyridine (4.85 mmol, 2.2 equiv) in 10 mL of dimethylformamide was heated at 100 °C under nitrogen for 3 hrs. An additional 0.132 mL of 3-bromopyridine (2.43 mmol, 1.1 equiv) was added and the reaction was maintained for an additional 2 hrs. The reaction mixture was cooled to ambient temperature, filtered through a sintered glass funnel and then evaporated in vacuo to a residue. The residue was partitioned between ethyl
30 acetate and aqueous ammonium hydroxide (5 mL conc. diluted to 100 mL). After
35 acetate and aqueous ammonium hydroxide (5 mL conc. diluted to 100 mL). After

separating the layers, the organic layer was washed with aqueous ammonium hydroxide (5 mL conc. diluted to 100 mL), and then saturated aqueous brine. The organic phase was then extracted three times with aqueous HCl (1N). The acid layers were combined and neutralized with aqueous sodium hydroxide (1N). The 5 neutralized mixture was extracted twice with methylene chloride. The methylene chloride layers were combined, dried over anhydrous sodium sulfate, filtered and evaporated in vacuo to a residue. The residue was triturated with hexane and then concentrated in vacuo to provide 0.705 g of the title compound as a tan solid. ¹H NMR (300 MHz, CDCl₃) δ 8.60 (m, 2H), 8.08 (b, 1H), 7.54 (b, 1H), 7.39 (m, 1H), 10 7.15 (m, 2H), 7.00 (m, 3H), 6.57 (dd, 1H, J = 2.7, 9.2), 4.95 (m, 1H), 4.32 (d, 1H, J = 17.9), 4.14 (d, 1H, J = 17.8), 3.85 (s, 3H), 3.61 (d, 1H, J = 12.1), 3.52 (d, 1H, J = 12.1), 1.06 (d, 6H, J = 6.8); low resolution MS (FAB)m/e 477 (MH⁺).

Intermediate 39

15 3-Nitro-benzoic acid t-butyl ester

Potassium t-butoxide solid (3.82 g, 32.30 mmol) was added to a solution of 3-nitrobenzoyl chloride (5.00 g, 26.94 mmol) in dry tetrahydrofuran (70 mL) and stirred under nitrogen for 2 hrs. The reaction mixture was concentrated in vacuo and 20 partitioned between dichloromethane and water. After separating the phases, the aqueous layer was back-extracted with ethyl acetate. The organic layers were combined, dried over anhydrous magnesium sulfate, filtered and then concentrated in vacuo. The crude product was purified on flash grade silica gel using 0-5% gradient of ethyl acetate in n-hexane. Fractions containing the product were 25 combined, concentrated in vacuo, and then dried under high vacuum to provide 3.82 g of the title compound as an oil. ¹H NMR (300 MHz, CDCl₃) δ 8.79 (m, 1H), 8.35 (m, 2H), 7.62 (m, 1H), 1.63 (s, 9H); low resolution MS (CI) m/e 224 (MH⁺).

Intermediate 40

30 3-Amino-benzoic acid t-butyl ester

A solution of 3-nitro-benzoic acid t-butyl ester (3.77 g, 16.9 mmol) in absolute ethanol (50 mL) was combined with palladium on carbon (10 wt%, 0.30 g) and hydrogenated under a balloon of hydrogen gas for approximately 3 hrs. The reaction 35 mixture was filtered through a pad of diatomaceous earth and then concentrated in

vacuo to an oil which crystallized when dried under high vacuum providing 3.28 g of the title compound as a tan solid. ¹H NMR (300 MHz, CDCl₃) δ 7.38 (d, 1H, J = 8.0 Hz), 7.29 (m, 1H), 7.19 (m, 1H), 6.83 (m, 1H), 1.58 (s, 9H); low resolution MS (CI) m/e 194 (MH⁺).

5

Intermediate 41

3-[(4-Nitrophenyl)oxycarbonyl]-amino-benzoic acid tert-butyl ester

A solution of 4-nitro-phenylchloroformate in dry dichloromethane (25 mL) was added dropwise over 20 min. to a solution of 3-amino-benzoic acid t-butyl ester (3.15 g, 10 16.24 mmol) and anhydrous pyridine (1.379 mL, 17.05 mmol) in anhydrous dichloromethane (25 mL) under nitrogen at 0-5 °C. The reaction mixture was allowed to warm to ambient temperature and stir overnight. After washing with aqueous HCl (1N), the reaction solution was dried over anhydrous magnesium sulfate and concentrated in vacuo to a solid. The crude product was slurried in n-hexane for 30 min., filtered and dried under high vacuum to provide 4.460 g of the title compound as a white crystalline solid. ¹H NMR (300 MHz, CDCl₃) δ 8.30 (m, 2H), 7.92 (m, 1H), 7.78 (d, 2H, J = 7.5 Hz), 7.43 (m, 3H), 7.11 (bs, 1H), 1.69 (s, 9H); low resolution MS (L-SIMS) m/e 358 (M⁺).

20

Intermediate 42

2-(3-Azido-7-fluoro-2,4-dioxo-5-pyridin-3-yl-2,3,4,5-tetrahydro-
benzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxy-phenyl)-acetamide

A solution of 262 mg of 2-(7-fluoro-2,4-dioxo-5-pyridin-3-yl-2,3,4,5-tetrahydro-25 benzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxy-phenyl)-acetamide (0.550 mmol) in 5 mL of anhydrous tetrahydrofuran at -78 °C under nitrogen was treated dropwise with 1.54 mL of potassium bis(trimethylsilyl)amide (0.5 M in toluene, 0.770 mmol, 1.4 eq). After stirring 15 min., 212 mg of 2,4,6-triisopropylbenzenesulfonyl azide (0.687 mmol, 1.25 eq, J. Org. Chem. 1984, 49, 1430-1434.) was added. After 30 stirring 4 min., the reaction mixture was quenched by addition of 78.6 mL of glacial acetic acid (1.38 mmol, 2.5 eq) and allowed to warm to ambient temperature. The reaction mixture was evaporated in vacuo to a residue and purified on flash grade silica with 1:1 ethyl acetate / hexane. The appropriate fractions were combined, evaporated in vacuo and dried under high vacuum to provide 170 mg of the title

compound as an amorphous solid. Low resolution MS (FAB)m/e 518 (MH+); TLC (silica) 3:1 Ethyl acetate : hexane Rf = 0.68.

Intermediate 43

5 2-(3-Amino-7-fluoro-2,4-dioxo-5-pyridin-3-yl-2,3,4,5-tetrahydro-
benzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxy-phenyl)-acetamide

A solution of 152 mg of 2-(3-azido-7-fluoro-2,4-dioxo-5-pyridin-3-yl-2,3,4,5-tetrahydro-benzo[b][1,4]diazepin-1-yl)-N-isopropyl-N-(4-methoxy-phenyl)-acetamide
10 in 10 mL of ethyl acetate was combined with 60 mg of palladium on carbon (10 wt%) and hydrogenated under a balloon of hydrogen gas for 16 hrs. The mixture was filtered, evaporated in vacuo and purified on flash grade silica gel using 3:7 methanol / ethyl acetate. The appropriate fractions were combined, evaporated in vacuo and dried under high vacuum to provide 82 mg of the title compound as a
15 foam. Low resolution MS (FAB)m/e 492 (MH+); TLC (silica) 95:5 dichloromethane / methanol Rf = 0.30.

Pharmacy Example

20 Tablet

Active Ingredient:	50 mg
Lactose anhydrous USP:	163 mg
Microcrystalline Cellulose NF:	69 mg
Pregelatinized starch Ph. Eur.	15 mg
25 Magnesium stearate USP	3 mg

Compression weight:	300 mg
---------------------	--------

The active ingredient, microcrystalline cellulose, lactose and pregelatinized starch
30 are sieved through a 500 micron sieve and blended in a suitable mixer. The magnesium stearate is sieved through a 250 micron sieve and blended with the active blend. The blend is compressed into tablets using suitable punches, then coated with cellulose acetate phthalate.

CCK-A RECEPTOR BINDING ASSAY**Tissue Preparation:**

Solutions of 0.3 M sucrose and 2.0 M sucrose were prepared and chilled overnight
5 at 4°C. On the following day, inhibitors were added such that the final concentrations were 0.01% Soybean Trypsin Inhibitor (50 mg/500 ml sucrose) and 100 mM phenylmethysulfonyl fluoride (8.5 mg/500 mL sucrose).

Rats were sacrificed by decapitation using a guillotine. The rat's external abdominal
10 wall was wetted with methanol and fur and skin were removed. The abdomen was opened, the pancreas was carefully dissected out and placed in a 50 mL beaker containing 0.3 M sucrose. After all the pancreata were harvested, excess fat and lymph nodes were trimmed off. Pancreatic tissue was divided into approximately 4.0 g aliquots into 30 mL beakers, each containing 1.0 mL of 0.3 M sucrose.

15 In 4°C cold room, the pancreata were minced with scissors and diluted 1:10 weight:volume with 0.3 M sucrose. Aliquots were homogenized in a chilled 40 mL Wheaton dounce with 4 up and down strokes of the "B" pestle followed by 4 up and down strokes of the "A" pestle. Homogenates were filtered through 2 layers of
20 cheesecloth into a chilled 500 mL beaker, then diluted with 2.0 M sucrose with stirring to yield a final concentration of 1.3 M sucrose homogenate. The resulting 1.3 M homogenate was dispensed into 18 thin-walled 36 mL polyallomer tubes on ice (approximately 30 mL homogenate per tube) and each tube was subsequently overlaid with 0.3 M sucrose until liquid was approximately 0.5 cm from the top of the
25 tube. The samples were spun in a Sorvall RC70 ultracentrifuge at 27,500 RPM (100,000 x g) for 3 hours at 4°C. The interface band was collected into a chilled graduated cylinder, diluted and mixed with cold distilled water to a total volume of 312 mL and spun at 100,000 x g for 50 min. at 4°C. The pellets were resuspended in KRH buffers, transferred to a 15 mL Wheaton dounce and homogenized with 4 up
30 and down strokes of the matched "A" (tight) pestle. This homogenate was transferred into 2-27 mL polycarbonate bottles and spun at 100,000 x g for 30 min. at 4°C. The pellet was resuspended (1 mL KRH buffer/gm wt of original tissue), transferred to an appropriate size dounce and homogenized with 4 up and down strokes of the matched "A" pestle. 1 mL aliquots are stored at -70°C in
35 microcentrifuge tubes.

KRH Buffer: pH = 7.4 at 4°C

	COMPONENT	MW	g/1 L
5	25 mM HEPES	260.3	6.51
	104 mM NaCl	58.44	6.08
	5 mM KCl	74.56	0.37
	1 mM KPO ₄	136.09	0.14
	1.2 mM MgSO ₄	246.48	0.30
	2 mM CaCl ₂	110.99	0.22
10	2.5 mM Glucose	180.16	0.45
	0.2% BSA	—	2.00
	0.1 mM PMSF*	174.2	0.017
	0.01% STI*	—	0.10

*inhibitors added fresh the day of the experiment

15

Assay:

Test compounds were diluted in assay binding buffer in stock concentrations 10-fold more concentrated than desired final assay concentration.

20 50 mL compound + 400 mL buffer + 25 mL [¹²⁵I] sulphated CCK-8 labeled with Bolton and Hunter reagent (Amersham, 2000 Ci/mmol) + 25 mL prepared rat pancreas membranes were incubated for 30 minutes at 25°C while shaking gently throughout the incubation.

25 1 mM L-364718 (final concentration) was used for determination of non-specific binding.

Reaction was stopped using Brandell Cell Harvester, washing 3X with 3 mL ice-cold (4°C) assay binding buffer per wash.

30

Tissues were collected on Whatman GF/B filter papers pre-wet with assay buffer and filter papers counted using a gamma counter.

CCK-B RECEPTOR BINDING ASSAY**Tissue Preparation:**

Hartley Male Guinea Pigs (250-300 g, Charles River) were sacrificed by decapitation. The brain was removed and placed in 4°C buffer (buffer = 50 mM 5 Tris/HCL, pH =7.4). The cortex was dissected and placed in 4°C buffer . The total wet weight of all cortices was determined and the tissues were diluted 1:10 (wt:vol) with buffer .

The cortex was minced using a Tekmar Tissuemizer then homogenized in buffer 10 with 5 up and down strokes using a motor driven glass/teflon homogenizer. The preparation was maintained at 4°C (on ice).

Membranes were pelleted by centrifugation in Sorvall RC5C at 4°C using a SA 600 rotor spun at 16,000 RPM (47,800 x g Maximum). The pellet was saved and the 15 supernatant was discarded. The pellets were combined and resuspended in buffer at 4°C using same volume as above and blended as above with 5 up and down strokes of a glass/teflon motor driven homogenizer using the same volume as before. The resulting homogenates were spun at 16,000 RPM (47,800 x g Maximum, 36,592 x g Average) for 15 minutes at 4°C. Pellets were saved and the 20 supernatants discarded. Pellets were subsequently combined with buffer to get a final volume of 300 mL and blended using a Tekmar Tissuemizer. Initial protein content was determined by the Biorad protein assay. The volume of suspension was adjusted with buffer, such that the volume adjustment yielded approximately 4.0 mg/mL as a final concentration, confirmed via the Biorad protein assay. The final 25 suspension was transferred as 4.0 mL aliquots into plastic tubes and frozen at -70°C.

Assay:

Buffer = 20 mM HEPES, 1 mM EGTA, 118 mM NaCl, 5 mM KCL, 5 mM MgCl₂, 30 0.05% BSA at pH = 7.4.

Skatron filters were soaked in buffer with 0.1% Bovine Serum Albumin (BSA) for an hour prior to harvesting.

100 mM Bestatin and 3 mM Phosphoramidon were prepared fresh. (Final assay concentrations will = 10 mM respectfully.)

Test compounds were diluted in assay binding buffer in stock concentrations 10-fold
5 more concentrated than desired final assay concentrations. [¹²⁵I]-sulfated CCK-8
labeled with Bolton-Hunter reagent (Amersham, 200 Ci/mmol) was diluted.

25 mL 100 mM Bestatin +25 mL 3 mM Phosphoramidon + 25 mL test compound +
50 mL radioligand + 25 mL buffer + 100 mL guinea pig cortex membranes were
10 incubated 150 minutes at room temperature.

For B₀ determination, assay binding buffer was substituted for test compound.

For filter binding determination, assay buffer was substituted for test compound and
15 guinea pig cortex membranes.

For non-specific binding determination, 1 mM sulphated CCK-8 (Sigma) was
substituted for test compound.

20 Reaction was stopped by filtering using the automated Skatron Cell Harvester. The
filters were rinsed using 4°C buffer. The filters were subsequently punched, placed
in tubes and counted using a gamma counter.

GUINEA PIG GALL BLADDER ASSAY

25

Tissue Preparation:

Gallbladders were removed from guinea pigs sacrificed by cervical dislocation. The
isolated gallbladders were cleaned of adherent connective tissue and cut into two
rings from each animal (2-4 mm in length). The rings were subsequently suspended
30 in organ chambers containing a physiological salt solution of the following
composition (mM): NaCl (118.4); KCl (4.7); MgSO₄ x H₂O (1.2); CaCl₂ x 2H₂O
(2.5); KH₂PO₃ (1.2); NaHCO₃ (25) and dextrose (11.1). The bathing solution was
maintained at 37°C and aerated with 95% O₂/5%CO₂. Tissues were connected via
gold chains and stainless steel mounting wires to isometric force displacement
35 transducers (Grass, Model FT03 D). Responses were then recorded on a

polygraph (Grass, Model 7E). One tissue from each animal served as a time/solvent control and did not receive test compound.

Assay:

5

Rings were gradually stretched (over a 120 min. period) to a basal resting tension of 1 gm which was maintained throughout the experiment. During the basal tension adjustment period, the rings were exposed to acetylcholine (ACH, 10^{-6} M) four times to verify tissue contractility. The tissues were then exposed to a submaximal 10 dose of sulfated CCK-8 (Sigma, 3×10^{-9} M). After obtaining a stable response, the tissues were washed out 3 times rapidly and every 5 to 10 minutes for 1 hour to reestablish a stable baseline.

Compounds were dissolved in dimethylsulfoxide (DMSO) then diluted with water 15 and assayed via a cumulative concentration-response curve to test compound (10^{-11} to 3×10^{-6} M) followed by a concentration-response curve to sulfated CCK-8 (10^{-10} to 10^{-6} M) in the presence of the highest dose of the test compound. As a final test, ACH (10 mM) was added to induce maximal contraction. A minimum of three determinations of activity were made for each test compound.

20

Results obtained in this test with representative compounds of the invention are given below. The compounds were tested at a concentration of $1\mu\text{M}$ and the results expressed as % sulfated CCK-8 maximal response.

Example No.	Contraction
1	91
2	64
3	83
4	67
5	51
6	32
7	77
8	81
10	83

60

11	67
13	96
14	84
15	93

18-HOUR DEPRIVATION-INDUCED FEEDING PARADIGM

Male, Long-Evans rats (Charles River Co., Raleigh, NC), weighing 300-375 grams, 5 were acclimated individually for at least a week in hanging, stainless steel mesh cages (17.8 X 25.4 X 17.8 cm high) with ad libitum access to water (delivered through automatic drinking spouts at the rear of the cage) and food (Lab Blox, Purina Rodent Laboratory Chow #5001) on a 12-hour light/dark cycle (lights on from 0600-1800 hours, or h) at approximately 22.8°C. Prior to testing, all chow, but not 10 water, was removed at 1600 h. At 0900 h the next morning, rats were weighed. At 0945 h, rats were injected intraperitoneally (i.p.), orally (per os, or p.o.) or through an indwelling, intra-duodenal cannulae with a test compound or vehicle (2 mL/kg) and returned to their home cages. Food was presented at 1000 h. At 1030 h, remaining food and spillage was weighed.


15

Compounds of the invention are essentially non toxic at therapeutically useful doses. Thus no untoward effects were observed when the compounds were administered to rats at therapeutically useful dose levels.

CLAIMS

1. A compound of the formula (I)


5



and physiologically salts thereof wherein:

10 X is either hydrogen, trifluoromethyl, alkyl, C1-4alkylthio, -O(C1-4alkyl) or halogen;

R1 is either Formula II or -NR⁴R⁵:



15 R² is either:

(1) a heterocycle linked at its 2- position and selected from pyrrole, tetrahydropyrrole, indole, benzofuran, thiophene, benzothiophene, indoline, quinoline or 4-oxobenzopyran and wherein said pyrrole,

20 tetrahydropyrrole, indole or indoline may optionally be substituted on the ring nitrogen thereof by the group R⁸ as defined hereunder and said indole, indoline, quinoline, benzofuran, benzothiophene or 4-oxo-benzopyran may optionally be substituted in the benzo ring thereof by the group R⁹ as defined hereunder or

(2) phenyl or phenyl mono- or disubstituted independently with halogen, hydroxy, cyano, carboxy, -O(C₁₋₄alkyl), -O(CH₂C₆H₅), -COO(C₁₋₄alkyl), amino, dimethylamino, -NHR¹⁰, 1-pyrrolidinyl or tetrazolyl; or

5

(3) pyridine or pyridinyl mono- or disubstituted independently with halogen, methyl, hydroxy, nitro, cyano, carboxy, -O(C₁₋₄ alkyl), -O(CH₂C₆H₅), -COO(C₁₋₄alkyl), amino or dimethylamino; or

10 (4) -NHR¹¹ where R¹¹ is defined hereinunder or R¹¹ is 7-indazolyl containing a group R¹⁰ at the N-1 position;

R³ is a heterocyclic group (attached to the rest of the molecule via a carbon atom ring member thereof), selected from pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, furanyl, thiophenyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, thiazolyl, thiadiazole, pyrrolidinyl, piperidinyl, morpholinyl or thiomorpholinyl which heterocyclic groups may be substituted with up to 3 substituents which may be the same or different and selected from halogen, C₁₋₄alkyl, nitro, carboxyl, C₁₋₄alkoxycarbonyl, C₁₋₄alkoxy, C₁₋₄alkylthio, amino, C₁₋₄alkylamino or di(C₁₋₄alkyl)amino.

R⁴ is independently C₃₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆alkenyl, phenyl, -(CH₂)_pCN or -(CH₂)_pCOO(C₁₋₄alkyl) and R⁵ is independently C₃₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆alkenyl, benzyl, phenyl or phenyl mono- or disubstituted independently with C₁₋₃alkyl optionally substituted by one or more fluorine atoms, cyano, hydroxy, dimethylamino, -O(C₁₋₄alkyl), -O(CH₂C₆H₅), -NH(C₁₋₄alkyl), -COO(C₁₋₄alkyl), -N(C₁₋₄alkyl)₂ pyrrolidino, morpholino or halogen or R⁴ is C₁₋₂alkyl and R⁵ is phenyl substituted at the 2- or 4- position with chloro, methyl, methoxy or methoxycarbonyl;

30 R⁶ is hydrogen or methyl;

R⁷ is hydrogen, hydroxy, fluoro, dimethylamino, -O(C₁₋₄alkyl) or -O(CH₂C₆H₅);

R⁸ is -(CH₂)_bCOOH;

63

R⁹ is methyl, chloro, nitro, hydroxy, methoxy or -NHR¹⁰;

R¹⁰ is hydrogen, acetyl, C₁-4alkyl, -SO₃H, -SO₂CH₃, -SO₂CF₃ or -SO₂C₆H₅, C₁-4alkoxycarbonyl;

5


R¹¹ is phenyl or phenyl mono- or disubstituted independently with fluorine, trifluoromethoxy, C₁-4alkylthio, -(CH₂)_cCOOH, -(CH₂)_cCOO(C₁-4alkyl), -(CH₂)_cSCH₃, -(CH₂)_cSOCH₃, -(CH₂)_cSO₂CH₃, -(CH₂)_cCONH₂, -SCH₂COOH, -CONH(SO₂CH₃), -CONH(SO₂CF₃), -(CH₂)_cN(C₁-4alkyl)₂, -(CH₂)_cNH(SO₂CF₃), -

10 (CH₂)_cN(SO₂CF₃)(C₁-4alkyl), -(CH₂)_cSO₂NHCO(C₁-4alkyl), -(CH₂)_cSO₂N(C₁-4alkyl)CO(C₁-4alkyl), -(CH₂)_cCONHSO₂(C₁-4alkyl), -(CH₂)_cCON(C₁-4alkyl)SO₂(C₁-4alkyl), -(CH₂)_cOR¹² -(CH₂)_cNHR¹⁰ or phenyl monosubstituted with -(CH₂)_c(tetrazolyl), -(CH₂)_c (carboxamidotetrazolyl) or -(CH₂)_c(pyrrolidinyl) or R¹¹ is selected from pyridine or pyridinyl mono- or disubstituted independently with

15 halogen, methyl, hydroxy, nitro, cyano, carboxy, -O(C₁-4 alkyl), amino, dimethylamino, -NHR¹⁰;

R¹² is hydrogen, C₁-6alkyl, C₃-6cycloalkyl, -CH₂C₆H₅, -CH₂COOH, -CH₂CONH₂, -CH₂CONH(C₁-4alkyl), -CH₂CON(C₁-4alkyl)₂ or

20



z is 1 or 2;

n is 1 or 2;

25

p is an integer from 1-4;

b is an integer from 0-3; and

30 c is 0 or 1.

2. A compound as claimed in claim 1 wherein R³ is a pyridyl, pyrimidinyl or 1, 3, 5-trimethyl-1H-pyrazol-4-yl group.
3. A compound as claimed in claim 1 or claim 2 wherein R³ is a -3-pyridyl group.
- 5 4. A compound as claimed in any of claims 1 to 3 wherein R⁴ is propyl or isopropyl and R⁵ is phenyl optionally substituted in the para position by a group selected from hydroxy, methoxy, fluoro, dimethylamino, pyrrolidino or morpholino.
- 10 5. A compound as claimed in any of claims 1 to 4 wherein R⁴ is isopropyl and R⁵ is 4-methoxyphenyl.
6. A compound a claimed in any of claims 1 to 5 wherein R² is indole, optionally substituted phenyl or NHR¹¹.
- 15 7. A compound as claimed in any of claims 1 to 6 wherein R² is indole or NHR¹¹ wherein R¹¹ is phenyl or 3-carboxyphenyl.
8. A compound as claimed in any of claims 1 to 7 wherein X is hydrogen or
20 fluorine.
9. H-Indole-2-carboxylic acid {1[isopropyl-(4-methoxy-phenyl)-carbamoylmethyl]-2,4-dioxo-5-pyridin-3-yl-2,3,4,5-tetrahydro-1H-benzo [b][1,4]diazepin-3-yl}-amide and enantiomers thereof.
- 25 10. A compound as claimed in any of claims 1-9 for use in therapy.
11. The use of a compound according to any of Claims 1 to 9 in the manufacture of a medicament for the treatment of conditions where a
30 modulation of the affects gastrin or CCK is of therapeutic benefit.
12. A method of treatment of a mammal including man for conditions where modulation of the effects of gastrin and/or CCK is of a therapeutic benefit comprising administration of an effective amount of a compound according to
35 any of Claims 1 to 9.

6.5


13. A pharmaceutical composition comprising a compound according to any of Claims 1 to 9 in an admixture with one or more physiologically acceptable carriers or excipients.

5

14. A process for the preparation of compounds as defined in Claim 1 which comprises:

(a) reacting a compound of Formula (III) wherein R¹, R³, X and z are as


10 defined in Formula (I)



with a compound R¹¹Y (IV) wherein Y is the group -NCO, HNCOCl or NHCOR_a
15 where R_a is nitro substituted phenoxy group or a 1-imidazole group.

wherein R¹¹ has the meaning defined in Formula (I) or is a group
convertible thereto.

20 (b) reacting a compound of Formula (V)



wherein R¹, R³ X and z have the meaning defined above and wherein Y is the group -NCO, -NHCOC_l or NHCOR_a wherein R_a is a nitro substituted phenoxy group or a 1-imidazole group with an amine (VI)


5

 $\text{H}_2\text{N}-\text{R}^{11}$ (VI)

10

wherein R¹¹ has the meaning defined in Formula (I) and is a group convertible thereto.

(c) reacting a compound of Formula (VII) wherein R³, R¹¹ and X are 15 as defined in Formula (I)




with the compound of Formula (VIII) wherein R¹ has the meanings defined in Formula (I)

20

 $\text{R}^1\text{COCH}_2\text{hal}$ (VIII)

(d) reacting a compound of Formula (III) wherein R¹, R³ X and Z are as 25 defined in Formula (I).



with an acid of Formula (IX) or an activated derivative thereof.

5

HOOC-R² (IX)

wherein R² has the meanings defined in Formula (I) or is a group convertible thereto;

10 and thereafter, if necessary or desired, converting the resultant compound into another compound of the invention.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 95/04163

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 C07K5/078 C07K5/097 A61K38/05 A61K38/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 6 C07K C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 376 849 (ROUSSEL-UCLAF) 4 July 1990 cited in the application see the whole document ---	1-14
A	WO,A,93 14074 (GLAXO SPA) 22 July 1993 see the whole document, particularly example 15 ---	1-14
P,X	WO,A,94 24149 (GLAXO INC.) 27 October 1994 see the whole document -----	1-14

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

3 July 1995

Date of mailing of the international search report

14.07.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Allard, M

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 95/04163

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP-A-376849	04-07-90	FR-A-	2641280	06-07-90
		JP-A-	2215774	28-08-90
		US-A-	4988692	29-01-91
WO-A-9314074	22-07-93	AU-A-	3193593	22-07-93
		AU-B-	3450193	03-08-93
		BG-A-	98881	31-03-95
		CA-A-	2087672	22-07-93
		CN-A-	1074678	28-07-93
		EP-A-	0558104	01-09-93
		FI-A-	943421	19-07-94
		HU-A-	67375	28-03-95
		JP-A-	7118244	09-05-95
		NO-A-	942720	20-07-94
WO-A-9424149	27-10-94	AU-B-	6567594	08-11-94
		AU-B-	6567694	08-11-94
		WO-A-	9424151	27-10-94

INTERNATIONAL SEARCH REPORT

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claim 12 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compounds/compositions~
2. Claims Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.